var title_f19_27_19888="Plasma cell";
var content_f19_27_19888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma cell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Description: Smear of the peripheral blood demonstrates a circulating plasma cell which is oval with abundant basophilic cytoplasm. The nucleus is round and eccentrically located with a marked prinuclear hof, or cytoplasmic clearing. The nucleus contains \"clock-face\" or \"spoke wheel\" chromatin without nucleoli.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anderson, SC, PhD. Anderson's Atlas of Hematology. Copyright 2003, Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19888=[""].join("\n");
var outline_f19_27_19888=null;
var title_f19_27_19889="NSAID induced strictures UGI";
var content_f19_27_19889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    NSAID-induced strictures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enteroclysis showing NSAID-induced strictures (between arrows) that are difficult to appreciate, and resembling exaggerated plica circularis. Diaphragm-like strictures confirmed at surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bjarnason I, et al. Side effects of nonsteroidal antiinflammatory drugs (NSAIDs) on the small and large intestine in humans. Gastroenterology 1993; 104:1832. Copyright &copy; 1993 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19889=[""].join("\n");
var outline_f19_27_19889=null;
var title_f19_27_19890="Patient information: Colon and rectal cancer (The Basics)";
var content_f19_27_19890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15412\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/29/42450\">",
"         Patient information: Bloody stools (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/9/38034\">",
"         Patient information: Colectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/38/11875\">",
"         Patient information: Colostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/0/6148\">",
"         Patient information: Colon and rectal cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/9/25747\">",
"         Patient information: Colon polyps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/22/40293\">",
"         Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Colon and rectal cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/colon-and-rectal-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H454757641\">",
"      <span class=\"h1\">",
"       What is colorectal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Colorectal cancer is cancer that affects the large intestine (also known as the colon) or the rectum (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). The word \"colorectal\" is just a shortened way of saying colon and rectal.",
"     </p>",
"     <p>",
"      Colorectal cancer can be serious. But there are many ways to treat it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454757648\">",
"      <span class=\"h1\">",
"       Is there a test for colorectal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are a few tests that can find colorectal cancer. Your doctor or nurse can explain your choices.",
"     </p>",
"     <p>",
"      If your doctor or nurse thinks you have colorectal cancer, he or she will probably suggest a test called a &ldquo;colonoscopy.&rdquo; During a colonoscopy, the doctor inserts a tube and a tiny camera into your anus and up to your colon. That way he or she can look for cancer or other problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454757655\">",
"      <span class=\"h1\">",
"       What are the symptoms of colorectal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Colorectal cancer may not cause any symptoms at first. When it does cause symptoms, it can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stomach pain",
"       </li>",
"       <li>",
"        A change in your bowel movements (number, texture, or size)",
"       </li>",
"       <li>",
"        Blood in your bowel movements",
"       </li>",
"       <li>",
"        Feeling weak or tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454757662\">",
"      <span class=\"h1\">",
"       How is colorectal cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most types of colorectal cancer are treated with one or more of these:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Surgery to remove the part of the colon or rectum that has cancer",
"       </li>",
"       <li>",
"        Medicine called chemotherapy that kills cancer cells",
"       </li>",
"       <li>",
"        Radiation therapy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454757669\">",
"      <span class=\"h1\">",
"       Will my body work normally after surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what type of surgery you have. If your doctor can reconnect your colon or rectum after removing the part with cancer, you should be able to have bowel movements normally. But if your doctor cannot reconnect your colon or rectum, he or she will make a hole in your belly and attach the end of the colon or a loop of intestine to that hole. The hole is called a &ldquo;colostomy.&rdquo; Your bowel movements will come out through the opening into a bag that is glued to your skin.",
"     </p>",
"     <p>",
"      Some people need to have a colostomy only for a short time. Then they can have another surgery to reconnect their colon or rectum. Other people need to have a colostomy for the rest of their life. If you need a colostomy, your doctor or nurse will put you in touch with people who can help you learn to use it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454757676\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After you finish treatment, you should see your doctor or nurse every so often for a few years. That way he or she can check to see if the cancer comes back. You will probably have to have blood tests every so often, a few more colonoscopy tests, plus a special kind of X-ray called a &ldquo;CT scan.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H454757683\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=see_link\">",
"       Patient information: Bloody stools (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"       Patient information: Colostomy care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"       Patient information: Colectomy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       Patient information: Colon and rectal cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"       Patient information: Colon polyps (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"       Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/27/19890?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15412 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19890=[""].join("\n");
var outline_f19_27_19890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454757641\">",
"      What is colorectal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454757648\">",
"      Is there a test for colorectal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454757655\">",
"      What are the symptoms of colorectal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454757662\">",
"      How is colorectal cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454757669\">",
"      Will my body work normally after surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454757676\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454757683\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15412\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=related_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=related_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=related_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_27_19891="Hawkins Kennedy test for shoulder impingement";
var content_f19_27_19891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hawkins Kennedy test for shoulder impingement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Hawkins Kennedy test is used to assess shoulder impingement. In this test the clinician stabilizes the shoulder with one hand and, with the patient's elbow flexed at 90 degrees, internally rotates the shoulder using the other hand. Shoulder pain elicited by internal rotation represents a positive test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD, J Bryan Dixon, MD, and David Kruse, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19891=[""].join("\n");
var outline_f19_27_19891=null;
var title_f19_27_19892="Chemical depigmentation";
var content_f19_27_19892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chemical depigmentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chemically induced depigmentation is limited to this patient's hands. Exposure to a cleaning product containing phenol caused the areas of hypopigmentation shown here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19892=[""].join("\n");
var outline_f19_27_19892=null;
var title_f19_27_19893="Spironolactone: Patient drug information";
var content_f19_27_19893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Spironolactone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     see \"Spironolactone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"     see \"Spironolactone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactone&reg;;",
"     </li>",
"     <li>",
"      Novo-Spiroton;",
"     </li>",
"     <li>",
"      Teva-Spironolactone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spironolactone can cause tumors in animals. These were long-term studies using larger doses than would be used in humans.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise potassium stores in the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702955",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to spironolactone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High potassium levels or kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for pimples (acne), you need to be at least 15 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after date on bottle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11872 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19893=[""].join("\n");
var outline_f19_27_19893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013293\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013295\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013294\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013299\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013300\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013302\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013297\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013298\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013303\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013304\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=related_link\">",
"      Spironolactone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=related_link\">",
"      Spironolactone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_27_19894="Bullous impetigo 2";
var content_f19_27_19894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86956%7EOBGYN%2F63992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86956%7EOBGYN%2F63992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Bullous impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19894=[""].join("\n");
var outline_f19_27_19894=null;
var title_f19_27_19895="Myofibroblast on electron microscopy";
var content_f19_27_19895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Myofibroblast on electron microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Myofibroblast viewed by electron microscopy. Myofibroblasts have an important role in the repair reaction. These cells, with features intermediate between those of smooth muscle cells and fibroblasts, are characterized by the presence of discrete bundles of myofilaments in the cytoplasm (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19895=[""].join("\n");
var outline_f19_27_19895=null;
var title_f19_27_19896="Retinitis pigmentosa: Clinical presentation and diagnosis";
var content_f19_27_19896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinitis pigmentosa: Clinical presentation and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19896/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19896/contributors\">",
"     Syndee Givre, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19896/contributors\">",
"     Seema Garg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19896/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19896/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19896/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/27/19896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinitis pigmentosa (RP) comprises a complex group of inherited dystrophies characterized by progressive degeneration and dysfunction of the retina, primarily affecting photoreceptor and pigment epithelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/1\">",
"     1",
"    </a>",
"    ]. RP may occur alone or as part of a syndrome, and may be inherited as a dominant, recessive, or X-linked trait, or occur sporadically. The same genetic mutation may cause different symptoms in different individuals, and the same syndrome may be caused by different mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Night and peripheral vision are lost progressively, leading to a constricted visual field and markedly diminished vision in some patients. Retinal degeneration can be seen on ophthalmoscopy as typical bone-spicule deposits or attenuated retinal vessels, or detected in early stages by special tests of retinal function.",
"   </p>",
"   <p>",
"    The term \"retinitis\" is a misnomer, since the pathogenesis is not inflammatory. Other terms for retinitis pigmentosa include \"rod-cone dystrophy,\" \"tapetoretinal degeneration,\" and \"pigmentary retinopathy.\"",
"   </p>",
"   <p>",
"    A family history of RP is present in about 70 percent of patients. The worldwide prevalence of RP is estimated at 1 in 4000 to 5000 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. About 100,000 patients are affected in the United States.",
"   </p>",
"   <p>",
"    This topic will discuss the natural history, diagnosis, and genetics of retinitis pigmentosa. Treatment and prognosis for retinitis pigmentosa are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17239?source=see_link\">",
"     \"Retinitis pigmentosa: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visual symptoms of retinitis pigmentosa arise primarily from the loss of retinal photoreceptors, both rods and cones.",
"   </p>",
"   <p>",
"    Night blindness (nyctalopia) is one of the earliest symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Patients may notice that they become disoriented in dim light, or that adaptation to dim light is slow, as in movie theaters. However, night blindness may go unrecognized until the disease is advanced, due to the insidious nature of RP and to pervasive artificial light sources; some patients never recognize night blindness as a symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive constriction of the visual field is another common feature. Patients may be considered \"clumsy\" before the diagnosis is made [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/6\">",
"     6",
"    </a>",
"    ]. The most common early pattern of visual field loss is loss in the midperiphery of the visual field (between 30 to 50 degrees eccentric to fixation, as this is where the density of rods is greatest), followed by extension of the visual loss into the far periphery of the visual field [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients may experience no impact from a decrement in visual field until the central visual field is reduced to about 50 degrees in diameter (normal is 180 degrees with both eyes open) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual acuity is variably affected. Patients may retain good visual acuity for years, despite extensive loss of peripheral vision. Eventually, most patients experience loss of visual acuity due to disease progression. In a study of 982 adult patients with RP, 52 percent had visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better in at least one eye and 25 percent had visual acuity of",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    or worse in both eyes. Only 5 percent had no light perception in both eyes. Patients with X-linked RP tend to have poorest visual acuity; those with autosomal dominant RP typically retain better visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cataracts and abnormalities in the central retina, such as macular edema or macular cysts, often contribute to deterioration in visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The functional impact of RP, in terms of difficulty with activities of daily living, correlates most strongly with loss of visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/14\">",
"     14",
"    </a>",
"    ]. Loss of visual field has less impact, and decrements detected by electroretinographic data correlate least well with activity impairment. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Full-field electroretinography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other symptoms commonly reported by patients with retinitis pigmentosa include photopsias (sensations of sparkling lights) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,8\">",
"     3,8",
"    </a>",
"    ] and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple patterns of inheritance, and underlying gene abnormalities, for disorders classified as retinitis pigmentosa. The same genetic mutation may cause different phenotypic patterns in different patients (phenotypic pleiotropy), and multiple genetic abnormalities may give rise to the same syndrome (allelic heterogeneity). A list of identified genes causing RP is available at the RetNet website (",
"    <a class=\"external\" href=\"file://www.sph.uth.tmc.edu/RetNet\">",
"     www.sph.uth.tmc.edu/RetNet",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining the specific genetic abnormality underlying RP can serve several functions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confirm the diagnosis of RP in equivocal cases",
"     </li>",
"     <li>",
"      Predict prognosis for patient and risk for other family members",
"     </li>",
"     <li>",
"      Identify types of RP for clinical trial eligibility, as gene-specific prevention and treatment protocols become available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, identifying the cause of the disease will contribute to a better understanding of the biology of the retina and its pathology.",
"   </p>",
"   <p>",
"    The typical form of retinitis pigmentosa, in which clinical manifestations are restricted to the eye (non-syndromic RP), comprises approximately 65 percent of all cases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/2\">",
"     2",
"    </a>",
"    ]. The distribution of inheritance patterns for these cases is approximately 30 percent autosomal dominant, 20 percent autosomal recessive, 15 percent X-linked, and 5 percent recessive early-onset (Leber congenital amaurosis or LCA). The remaining 30 percent are sporadic.",
"   </p>",
"   <p>",
"    Autosomal dominant retinitis pigmentosa confers a 50 percent risk to the offspring of affected individuals. In autosomal recessive retinitis pigmentosa, each child has a 25 percent risk of being affected if both parents are carriers. X-linked retinitis pigmentosa patients are typically male. However, female carriers of X-linked retinitis pigmentosa may have visual symptoms. Affected males cannot transmit the abnormal gene to their sons, but all daughters will be carriers. Where there is no family history of RP and an abnormal gene cannot be determined, the risk of RP affecting offspring is less than 5 percent, unless there is consanguinity in the family [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to typical forms of retinitis pigmentosa, syndromic forms exist that involve multiple organs. The most common form of syndromic RP is Usher syndrome. Usher patients have congenital or early-onset hearing impairment followed by development of RP. Bardet-Biedl syndrome is the next most common syndromic form, and is associated with polydactyly, obesity, renal abnormalities, and mental retardation. Mutations involving the nephronophthisis (NPHP) genes are well characterized and cause childhood endstage renal disease and retinitis pigmentosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linkage analyses in families with multiple affected individuals have resulted in the identification of numerous genomic regions that harbor mutations causing RP. The first retinitis pigmentosa mutation was identified in 1989 in the rhodopsin gene (RHO) on chromosome 3q21.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/16\">",
"     16",
"    </a>",
"    ]. Rhodopsin is a light absorbing pigment in the membrane of the rod photoreceptor cell. A proline-to-histidine change at amino acid 23 in this gene was found in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/17\">",
"     17",
"    </a>",
"    ]. This mutation alone accounts for 10 percent of autosomal dominant RP in the US Caucasian population.",
"   </p>",
"   <p>",
"    The pace of discovery has been exponential, as now more than 100 different rhodopsin mutations are known. Thus far, over 51 genes have been implicated in non-syndromic RP, 45 genes in syndromic RP, and 10 genes in LCA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/15\">",
"     15",
"    </a>",
"    ]. The protein products of these genes are involved in multiple pathways: the phototransduction cascade; vitamin A metabolism; cytoskeletal structures; signaling and cell to cell interactions; RNA intron splicing factors; regulation of intracellular protein traffic; and phagocytosis.",
"   </p>",
"   <p>",
"    The three most common genes implicated in RP, accounting for approximately 30 percent of all retinitis pigmentosa in 2007, are [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RHO (&gt;26 percent of autosomal dominant RP).",
"     </li>",
"     <li>",
"      USH2A, also known as Usherin (10 percent of autosomal recessive RP). USH 2A can be mutated to cause both nonsyndromic RP and syndromic RP as part of the Usher Syndrome.",
"     </li>",
"     <li>",
"      RPGR, retinitis pigmentosa GTPase regulator (~75 percent of X-linked retinitis pigmentosa).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another gene, EYS, a homolog of Drosophila eyes shut, was identified in 2008 as the gene responsible for autosomal recessive RP at the RP25 locus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/18\">",
"     18",
"    </a>",
"    ]. This gene may be involved in a significant proportion of patients with autosomal recessive RP from diverse geographic ancestries worldwide. This is the largest eye gene identified (spanning more than 2 million DNA base pairs), and may be involved in production of a protein necessary for maintaining mechanical support and rigidity of the outer segment of the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible to detect disease-causing mutations in over 50 percent of patients with autosomal dominant RP, 30 percent of patients with recessive RP, 70 percent of patients with recessive LCA, and nearly 90 percent of patients with X-linked RP. Widespread genetic testing is expected to become available in the near future, as the identification of the specific retinitis pigmentosa genes becomes more clinically relevant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/20\">",
"     20",
"    </a>",
"    ]. In 2006, the National Eye Institute developed the eyeGENE",
"    <sup>",
"     TM",
"    </sup>",
"    program to provide a repository and genetic testing for several inherited eye diseases, including retinitis pigmentosa and retinal degenerations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of retinitis pigmentosa is variable, affecting some patients with visual loss in childhood while others are asymptomatic well into adulthood. The typical course of retinitis pigmentosa is gradual loss of visual field, visual acuity and electroretinographic activity over time. Central retinal function declines more slowly than more peripheral retinal function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. Most patients meet criteria for legal blindness by age 40, due to narrowing of visual fields [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two longitudinal studies of patients with RP, followed for three and nine years, the visual field diminished at a rate of 4.6 to 12 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. Three distinct patterns of visual field loss were identified in another longitudinal study: progressive, generalized constriction; expansion from a midperipheral ring scotoma; or loss beginning superiorly and expanding nasally or temporally [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/23\">",
"     23",
"    </a>",
"    ]. The patterns of visual field loss within a particular family did not vary.",
"   </p>",
"   <p>",
"    Visual acuity declines more slowly than loss of visual fields [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. The presence of macular lesions on initial presentation is associated with greater loss of visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with a normal macula lost on average 1 line of visual acuity over five years while patients with a macular lesion lost an average of 3 to 4 lines over five years.",
"   </p>",
"   <p>",
"    Measurement of cone electroretinograms may help estimate the long-term visual prognosis for a given patient, and serial measurements can help refine this prediction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Full-field electroretinography'",
"    </a>",
"    below.) In one report, an estimated 25 percent of patients with typical RP at initial presentation were over 40 years old and had a cone amplitude &ge;3.5 microV; on average, such patients would be expected to retain some vision throughout their lifespan without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age of symptom onset, ranging from childhood to adulthood, does not correlate well with the onset of photoreceptor degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANATOMIC ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Retina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic ophthalmoscopic findings in retinitis pigmentosa are described as a triad: attenuation of the retinal blood vessels, waxy pallor of the optic disc, and intraretinal pigmentation in a bone-spicule pattern (",
"    <a class=\"graphic graphic_picture graphicRef81281 \" href=\"UTD.htm?43/24/44418\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53849 \" href=\"UTD.htm?5/43/5811\">",
"     picture 2",
"    </a>",
"    ). Retinal vascular attenuation was found in 94 percent of 384 eyes and optic disc pallor in 52 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optic disc has a waxy, pale appearance thought to be due to both optic disc atrophy and gliosis overlying the disc [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. Drusen of the optic disc (hyaline-like, acellular, laminated globular excrescences) are due to aberrant axonal transport and are more common in patients with retinitis pigmentosa than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The retina may appear normal in early states of retinitis pigmentosa, even though electrophysiologic testing reveals dysfunction of the photoreceptors. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Full-field electroretinography'",
"    </a>",
"    below.) This \"early\" stage may last for decades [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3\">",
"     3",
"    </a>",
"    ]. As the disease advances, the retinal vessels become more attenuated until they appear thread-like.",
"   </p>",
"   <p>",
"    Abnormal retinal pigmentation develops when pigment migrates from disintegrating retinal pigment epithelial cells into the superficial (\"inner\") retina in response to photoreceptor cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef67585 \" href=\"UTD.htm?42/53/43861\">",
"     figure 1",
"    </a>",
"    ). The pigmentary abnormality is visible initially as a dusting of fine pigment extending from the mid to far peripheral retina. Later, \"bone-spicules\" (accumulations of pigment along the interstitial spaces surrounding retinal blood vessels) form throughout the mid and far retinal periphery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/30\">",
"     30",
"    </a>",
"    ]. Atrophy of the choriocapillaris may be present in advanced retinitis pigmentosa, exposing the large choroidal vessels underneath [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Macula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The macula, or central retina, becomes affected in moderate or advanced disease, when photoreceptor degeneration advances and leads to retinal thinning and loss of visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/6,12,27,31\">",
"     6,12,27,31",
"    </a>",
"    ]. A central atrophic or bulls-eye lesion will be visible in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may also develop cellophane maculopathy (also called \"surface wrinkling retinopathy\") and foveal cysts, with or without associated edema [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/12,13,27\">",
"     12,13,27",
"    </a>",
"    ]. These problems compound the loss of visual acuity due to photoreceptor death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataracts, especially posterior subcapsular cataracts, affect approximately 50 percent of patients with retinitis pigmentosa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,4,6,27,32\">",
"     3,4,6,27,32",
"    </a>",
"    ]. Cataract prevalence is higher in the autosomal dominant subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vitreous",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vitreous may contain a dust-like pigmented substance, comprised of pigment granules [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/8\">",
"     8",
"    </a>",
"    ]. Complete posterior vitreous detachment is more common than in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,4,6,7,27,33\">",
"     3,4,6,7,27,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FUNCTIONAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Refractive error",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinitis pigmentosa is associated with astigmatism and myopia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,6,34\">",
"     3,6,34",
"    </a>",
"    ]. In one study, myopia was present in 75 percent of 268 eyes of patients with retinitis pigmentosa, and in only 12 percent of a normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/34\">",
"     34",
"    </a>",
"    ]. The prevalence of myopia is higher in patients with X-linked RP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2329?source=see_link\">",
"     \"Visual impairment in adults: Refractive disorders and presbyopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Visual acuity and visual fields",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual loss in retinitis pigmentosa usually begins with mid-peripheral scotomata that progress over time to involve the entire periphery. Loss of photoreceptors in the macula in advanced disease leads to progressive constriction of the central visual field and worsening visual acuity. Patients are left with a central island of vision that gradually constricts over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Contrast sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard visual acuity is measured at high contrast. The ability to distinguish low contrast objects is another measure of visual function that is diminished in patients with RP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/35\">",
"     35",
"    </a>",
"    ]. Loss of contrast sensitivity may contribute to patients' perception of decreased vision when standard visual acuity testing is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Color vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color vision remains normal until the macula becomes involved and visual acuity is reduced. When color vision is affected, testing usually reveals a blue cone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,5,7\">",
"     3,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dark adaptometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dark adaptometry is a psychophysical measurement of the visual threshold to a light stimulus. After being exposed to a bright light stimulus, subjects are placed in the dark for 30 minutes, and the minimum intensity light that can be detected by the subject is measured at interval time points.",
"   </p>",
"   <p>",
"    In normal subjects, there is an initial increase in sensitivity to low light, a phenomenon mediated by cone photoreceptors, that reaches a plateau within five minutes. Subsequently, the rod system progressively activates and sensitivity to light increases again until a second plateau is reached. Abnormalities of dark adaptometry in RP include loss of rod sensitivity, or loss of both rod and cone sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/3,5,6,36\">",
"     3,5,6,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Full-field electroretinography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electroretinogram (ERG), a mainstay in the diagnosis of retinitis pigmentosa since the early 1950s, measures the electrical response of the retina to light stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/37\">",
"     37",
"    </a>",
"    ]. Full-field electroretinography, the traditional standard, activates the entire retina simultaneously. An electrode is placed on the cornea or on the skin of the eyelid and the color and the intensity of a light stimulus are manipulated to activate the cones or rods, separately or together.",
"   </p>",
"   <p>",
"    Retinitis pigmentosa causes a reduction in the amplitude and a delay in the timing of the electrical signal produced by retinal stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/38\">",
"     38",
"    </a>",
"    ]. The amplitude of the electroretinogram correlates well with the size of the remaining visual field [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with moderate or advanced RP have a non-recordable (extinguished) electroretinogram.",
"   </p>",
"   <p>",
"    The electroretinogram may be abnormal even in early stages of the disease, when the retina appears normal. Full-field electroretinography is invaluable in detecting retinitis pigmentosa in patients at risk for the disease (eg, family members of diagnosed patients) who have normal-appearing retinas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Multifocal electroretinography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal electroretinography records the local electrical signal generated by the stimulation of a discrete portion of the retina. Multifocal electroretinography, a more recent technique, permits the recording of many focal electroretinograms simultaneously and represents central cone function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The multifocal electroretinogram is useful in monitoring patients with retinitis pigmentosa in later stages of the disease. This technique can record electroretinographic responses generated within the functioning maculae in patients who have nearly extinguished full-field electroretinograms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several acquired conditions cause extensive chorioretinopathy and may be confused with retinitis pigmentosa. These include traumatic retinopathy, retinal inflammatory diseases, paraneoplastic retinopathy, drug toxicity, and rare conditions such as diffuse unilateral subacute neuroretinitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Traumatic retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic retinopathy is the most common masquerader of retinitis pigmentosa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/44\">",
"     44",
"    </a>",
"    ]. Several months after blunt or penetrating injury to the eye, the retina may assume an appearance similar to that of RP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/45\">",
"     45",
"    </a>",
"    ]. The retinal pigment epithelium becomes atrophic and dark retinal pigment migrates into the superficial retina, especially along retinal vessels. This bone-spicule pattern is sometimes indistinguishable from that seen in RP. These changes do result in visual loss but, in contrast to RP, the loss is not progressive over time and the ERG may even be normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Retinal inflammatory diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigmentary retinopathies may occur in rubella, syphilis, toxoplasmosis, and herpesvirus infection of the retina. Rubella retinopathy is the most common ocular manifestation of congenital rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/46\">",
"     46",
"    </a>",
"    ]. If a child has congenital hearing loss secondary to rubella infection and concurrent rubella retinopathy, the child may be mistakenly diagnosed with Usher syndrome, a genetic disorder affecting the cochlea and retina. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetics'",
"    </a>",
"    above.) Electroretinography may facilitate the correct diagnosis, as the electroretinogram is only mildly abnormal in rubella, but severely abnormal in Usher syndrome.",
"   </p>",
"   <p>",
"    Congenital or acquired syphilis may mimic advanced RP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/47\">",
"     47",
"    </a>",
"    ]. However, unlike RP, syphilis produces patchy pigmentary retinal changes and chorioretinal scars.",
"   </p>",
"   <p>",
"    Toxoplasmosis or herpes infections of the retina may also produce a pigmentary retinopathy. Random patches of severe retinopathy occur with these infections, similar to syphilis retinopathy. The electroretinogram is usually only mildly abnormal in inflammatory pigmentary retinopathies but markedly abnormal in RP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Autoimmune paraneoplastic retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, panretinal degeneration can accompany certain cancers, particularly small-cell lung and cervical carcinoma. The electroretinogram is usually severely abnormal. Cancer-associated retinopathy (CAR) is thought to be due to autoantibodies to recoverin and enolase in the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/48\">",
"     48",
"    </a>",
"    ]. Melanoma-associated retinopathy (MAR) presents with night blindness, but has a unique ERG pattern distinguishable from that of RP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7239?source=see_link\">",
"     \"Paraneoplastic visual syndromes\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenothiazines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    bind to melanin and concentrate in the retinal pigment epithelium.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     Thioridazine",
"    </a>",
"    in doses higher than 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    can cause severe retinal toxicity. This toxicity may manifest as a pigmentary retinopathy that mimics early retinitis pigmentosa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    retinopathy may develop when total doses exceed 300 g [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19896/abstract/50\">",
"     50",
"    </a>",
"    ]. Bone-spicules may develop in the peripheral retina, but unlike retinitis pigmentosa, dark adaptometry is usually normal.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    retinopathy, which is less common than chloroquine retinopathy, may develop after medication use for longer than five years, and at a dose of greater than 6.5",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    The retinopathy is typically milder than chloroquine retinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diffuse unilateral subacute neuroretinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse unilateral subacute neuroretinitis (DUSN) is a rare panretinal degeneration secondary to infection with the worms Baylisascaris procyonis and Toxocara canis. In the late stages, the fundus appearance resembles that of advanced retinitis pigmentosa, but unlike retinitis pigmentosa the abnormalities are typically restricted to one eye. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=see_link\">",
"     \"Toxocariasis: visceral and ocular larva migrans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=see_link\">",
"     \"Anthelminthic therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/28/4546?source=see_link\">",
"       \"Patient information: Retinitis pigmentosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinitis pigmentosa (RP) comprises a group of inherited conditions that cause progressive retinal degeneration and affect the photoreceptors and retinal pigment epithelium. A family history is identified in about 70 percent of patients; there are multiple inheritance patterns. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Night blindness is one of the earliest symptoms, but can be so gradual that it may go unnoticed by patients. Loss of visual field is progressive, starting in the midperiphery and progressing more peripherally, resulting in a constricted visual field. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptoms and presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over 51 genes have been implicated in RP. RP occurs in a simple form in the majority of patients, but may also occur as part of a syndrome involving other organs. There is variability of the phenotype depending on the specific gene mutation. Compared to other inherited types of RP, X-linked RP is generally associated with a more severe clinical picture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Age of symptom onset ranges from childhood to adulthood, but photoreceptor degeneration can be detected many years before affected individuals are aware of vision problems. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in the ocular fundus seen on ophthalmoscopy are optic disc pallor, attenuated vessels, and pigment deposits in a bone-spicule pattern. The macula may be affected in advanced disease. Cataracts may further compromise central vision. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Anatomic abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic tests include dark adaptometry, full-field and multifocal electroretinography (ERG). ERG may be used to detect disease in asymptomatic individuals and project the course of vision loss. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired conditions resulting in ophthalmoscopic findings resembling RP include ocular trauma, ocular inflammation associated with infection (rubella, syphilis, toxoplasmosis, herpesvirus), paraneoplastic retinopathy, and drug toxicity (phenothiazines and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/1\">",
"      Retinitis pigmentosa. A symposium on terminology and methods of examination. Ophthalmology 1983; 90:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/2\">",
"      Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol 2007; 125:151.",
"     </a>",
"    </li>",
"    <li>",
"     Weleber RG, Gregory-Evans K. Retinitis Pigmentosa and Allied Disorders. In: Retina, Ryan SJ (Ed), Elsevier Mosby, 2006. p.395.",
"    </li>",
"    <li>",
"     Berson EL. Retinitis pigmentosa and allied retinal diseases. In: Duane's Clinical Ophthalmology, Tasman W, Jaeger EA (Eds), Lippincott, Williams &amp; Wilkins, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/5\">",
"      Merin S, Auerbach E. Retinitis pigmentosa. Surv Ophthalmol 1976; 20:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/6\">",
"      Pagon RA. Retinitis pigmentosa. Surv Ophthalmol 1988; 33:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/7\">",
"      Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006; 368:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/8\">",
"      Heckenlively JR, Yoser SL, Friedman LH, Oversier JJ. Clinical findings and common symptoms in retinitis pigmentosa. Am J Ophthalmol 1988; 105:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/9\">",
"      Berson EL, Sandberg MA, Rosner B, et al. Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol 1985; 99:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/10\">",
"      Grover S, Fishman GA, Anderson RJ, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology 1999; 106:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/11\">",
"      Berson EL, Rosner B, Simonoff E. Risk factors for genetic typing and detection in retinitis pigmentosa. Am J Ophthalmol 1980; 89:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/12\">",
"      Fishman GA, Fishman M, Maggiano J. Macular lesions associated with retinitis pigmentosa. Arch Ophthalmol 1977; 95:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/13\">",
"      Fishman GA, Maggiano JM, Fishman M. Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol 1977; 95:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/14\">",
"      Szlyk JP, Fishman GA, Alexander KR, et al. Relationship between difficulty in performing daily activities and clinical measures of visual function in patients with retinitis pigmentosa. Arch Ophthalmol 1997; 115:53.",
"     </a>",
"    </li>",
"    <li>",
"     Daiger SP. The University of Texas Heatlh Science Center. RetNet: Retinal Information Network. Available at: www.sph.uth.tmc.edu/RetNet (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/16\">",
"      McWilliam P, Farrar GJ, Kenna P, et al. Autosomal dominant retinitis pigmentosa (ADRP): localization of an ADRP gene to the long arm of chromosome 3. Genomics 1989; 5:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/17\">",
"      Dryja TP, McGee TL, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 1990; 343:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/18\">",
"      Abd El-Aziz MM, Barragan I, O'Driscoll CA, et al. EYS, encoding an ortholog of Drosophila spacemaker, is mutated in autosomal recessive retinitis pigmentosa. Nat Genet 2008; 40:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/19\">",
"      Cook B, Zelhof AC. Photoreceptors in evolution and disease. Nat Genet 2008; 40:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/20\">",
"      Walia S, Fishman GA, Jacobson SG, et al. Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa. Ophthalmology 2010; 117:1190.",
"     </a>",
"    </li>",
"    <li>",
"     National Eye Institute. National Ophthalmic Disease Genotyping Network (eyeGENETM). Available at: www.nei.nih.gov.libproxy.lib.unc.edu/resources/eyegene.asp (Accessed on August 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/22\">",
"      Holopigian K, Greenstein V, Seiple W, Carr RE. Rates of change differ among measures of visual function in patients with retinitis pigmentosa. Ophthalmology 1996; 103:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/23\">",
"      Grover S, Fishman GA, Brown J Jr. Patterns of visual field progression in patients with retinitis pigmentosa. Ophthalmology 1998; 105:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/24\">",
"      Flynn MF, Fishman GA, Anderson RJ, Roberts DK. Retrospective longitudinal study of visual acuity change in patients with retinitis pigmentosa. Retina 2001; 21:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/25\">",
"      Berson EL. Long-term visual prognoses in patients with retinitis pigmentosa: the Ludwig von Sallmann lecture. Exp Eye Res 2007; 85:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/26\">",
"      Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. Invest Ophthalmol Vis Sci 1993; 34:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/27\">",
"      Pruett RC. Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol Soc 1983; 81:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/28\">",
"      Novack RL, Foos RY. Drusen of the optic disk in retinitis pigmentosa. Am J Ophthalmol 1987; 103:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/29\">",
"      Grover S, Fishman GA, Brown J Jr. Frequency of optic disc or parapapillary nerve fiber layer drusen in retinitis pigmentosa. Ophthalmology 1997; 104:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/30\">",
"      Li ZY, Possin DE, Milam AH. Histopathology of bone spicule pigmentation in retinitis pigmentosa. Ophthalmology 1995; 102:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/31\">",
"      Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL. The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2005; 46:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/32\">",
"      Heckenlively J. The frequency of posterior subcapsular cataract in the hereditary retinal degenerations. Am J Ophthalmol 1982; 93:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/33\">",
"      Takahashi M, Jalkh A, Hoskins J, et al. Biomicroscopic evaluation and photography of liquefied vitreous in some vitreoretinal disorders. Arch Ophthalmol 1981; 99:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/34\">",
"      Sieving PA, Fishman GA. Refractive errors of retinitis pigmentosa patients. Br J Ophthalmol 1978; 62:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/35\">",
"      Lindberg CR, Fishman GA, Anderson RJ, Vasquez V. Contrast sensitivity in retinitis pigmentosa. Br J Ophthalmol 1981; 65:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/36\">",
"      GOODMAN G, GUNKEL RD. Familial electroretinographic and adaptometric studies in retinitis pigmentosa. Am J Ophthalmol 1958; 46:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/37\">",
"      Bjork A, Karpe G. The electroretinogram in retinitis pigmentosa. Acta Ophthalmol Scand 1951; 29:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/38\">",
"      Berson EL. Retinitis pigmentosa and allied retinal diseases: electrophysiologic findings. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1976; 81:OP659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/39\">",
"      Sandberg MA, Weigel-DiFranco C, Rosner B, Berson EL. The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1996; 37:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/40\">",
"      Sutter EE, Tran D. The field topography of ERG components in man--I. The photopic luminance response. Vision Res 1992; 32:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/41\">",
"      Hood DC, Holopigian K, Greenstein V, et al. Assessment of local retinal function in patients with retinitis pigmentosa using the multi-focal ERG technique. Vision Res 1998; 38:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/42\">",
"      Seeliger M, Kretschmann U, Apfelstedt-Sylla E, et al. Multifocal electroretinography in retinitis pigmentosa. Am J Ophthalmol 1998; 125:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/43\">",
"      Gr&auml;nse L, Ponjavic V, Andr&eacute;asson S. Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields. Acta Ophthalmol Scand 2004; 82:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/44\">",
"      Bastek JV, Foos RY, Heckenlively J. Traumatic pigmentary retinopathy. Am J Ophthalmol 1981; 92:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/45\">",
"      Cogan DG. Pseudoretinitis pigmentosa. Report of two traumatic cases of recent origin. Arch Ophthalmol 1969; 81:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/46\">",
"      Cooper LZ, Krugman S. Clinical manifestations of postnatal and congenital rubella. Arch Ophthalmol 1967; 77:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/47\">",
"      Heckenlively JR. Secondary retinitis pigmentosa (syphilis). Doc Ophthalmol Proc Serv 1977; 13:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/48\">",
"      Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004; 4:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/49\">",
"      Hamilton JD. Thioridazine retinopathy within the upper dosage limit. Psychosomatics 1985; 26:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19896/abstract/50\">",
"      Marks JS. Chloroquine retinopathy: is there a safe daily dose? Ann Rheum Dis 1982; 41:52.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6905 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19896=[""].join("\n");
var outline_f19_27_19896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS AND PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gene mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANATOMIC ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Retina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Macula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vitreous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FUNCTIONAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Refractive error",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Visual acuity and visual fields",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Contrast sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Color vision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dark adaptometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Full-field electroretinography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Multifocal electroretinography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Traumatic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Retinal inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Autoimmune paraneoplastic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diffuse unilateral subacute neuroretinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6905|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/53/43861\" title=\"figure 1\">",
"      Histology healthy vs RP retina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6905|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/24/44418\" title=\"picture 1\">",
"      Ocular fundus in pt with RP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/43/5811\" title=\"picture 2\">",
"      Advanced RP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=related_link\">",
"      Anthelminthic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7239?source=related_link\">",
"      Paraneoplastic visual syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/28/4546?source=related_link\">",
"      Patient information: Retinitis pigmentosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17239?source=related_link\">",
"      Retinitis pigmentosa: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=related_link\">",
"      Toxocariasis: visceral and ocular larva migrans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2329?source=related_link\">",
"      Visual impairment in adults: Refractive disorders and presbyopia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_27_19897="Treatment of metastatic urothelial cancer of the bladder and urinary tract";
var content_f19_27_19897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Gary R MacVicar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Joaquim Bellmunt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Maha Hussain, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Derek Raghavan, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19897/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/27/19897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is the most common malignancy involving the urinary system. Urothelial (transitional cell) carcinoma is the predominant histologic type in the United States and Europe, where it accounts for 90 percent of all bladder cancers. In other areas of the world, non-urothelial carcinomas are more frequent. Much less commonly, urothelial cancers can arise in the renal pelvis, ureter, or urethra. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=see_link\">",
"     \"Urethral cancer in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=see_link\">",
"     \"Urethral cancer in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients will have muscle-invasive disease and either present with or later develop metastases. Systemic chemotherapy is the standard approach for patients with inoperable locally advanced or metastatic urothelial malignancies. Although initial response rates are high, the median survival with multiagent chemotherapy is about 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While this is superior to the estimated six-month survival with metastatic disease prior to the development of modern chemotherapy regimens, the five-year survival rate is about 15 percent with contemporary regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The approach to systemic treatment for metastatic disease of urothelial cancer of the renal pelvis or ureter is based upon results from trials composed primarily of patients with urothelial carcinoma of the bladder.",
"   </p>",
"   <p>",
"    Systemic chemotherapy for metastatic urothelial cancer is reviewed here. The use of chemotherapy as a neoadjuvant or adjuvant in conjunction with cystectomy and as part of a multimodality approach to preserve the bladder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link\">",
"     \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=see_link\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2740504\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical and molecular characteristics are correlated with survival. An appreciation of these prognostic factors is important for the interpretation of clinical trials results and for determining which patients may benefit from therapy. (See",
"    <a class=\"local\" href=\"#H1495808759\">",
"     'Defining medical fitness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495807775\">",
"    <span class=\"h2\">",
"     Clinical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A poor performance status and the presence of visceral (ie, pulmonary, liver, bone) metastases correlate with shortened survival in clinical trials. This was illustrated by an Intergroup trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    alone to MVAC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , cisplatin) in patients with metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of bone or liver metastases and poor performance status were most predictive of poor response and survival. The presence of these unfavorable features was associated with a median survival of 4 months, compared to 18 months in those patients without these features [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No patients with liver or bone metastases and only one patient with a Karnofsky performance status (KPS) &lt;80 percent survived six years (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several subsequent reports confirmed the relationship between shortened survival and poor performance status or the presence of visceral metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/2,6-9\">",
"     2,6-9",
"    </a>",
"    ]. Similar to the first-line setting, the presence of liver metastases, poor performance status, and a low hemoglobin level appear to predict a worse outcome in the second-line setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495807782\">",
"    <span class=\"h2\">",
"     Molecular factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular abnormalities are also being studied as",
"    <span class=\"nowrap\">",
"     prognostic/predictive",
"    </span>",
"    factors, with the goal of using the molecular characteristics of an individual tumor to help select treatment and to predict outcome. However, none of these factors have been validated and should not be used to make clinical decisions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of mutations in the p53 gene has been extensively studied but remains uncertain. Multiple studies have suggested that such mutations are associated with resistance to MVAC chemotherapy and a poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/11-15\">",
"       11-15",
"      </a>",
"      ]. In contrast, at least one report found that tumors with p53 mutations have a worse tumor-specific prognosis but with potentially increased sensitivity to the MVAC or equivalent regimen, at least in the adjuvant setting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/16\">",
"       16",
"      </a>",
"      ]. In an analysis of another trial, the presence of p53 mutations was neither predictive nor prognostic [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The excision repair cross complementing 1 (ERCC1) gene is involved in DNA repair and may mediate resistance to alkylating agent chemotherapy. In a study of 57 patients with advanced bladder cancer who were treated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimen, the median survival was significantly longer in patients with low ERCC1 levels (25 versus 15 months in those with high ERCC1 expression) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other potential markers of chemotherapy resistance include the multidrug resistance p-glycoprotein, multidrug resistance associated protein, glutathione, and metallothioneins [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/19-23\">",
"       19-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy regimen is the preferred initial therapy for patients with metastatic urothelial cancer of the bladder and urinary tract who are cisplatin candidates. As described below, cisplatin-based combination chemotherapy results in superior survival when compared with single agent cisplatin. However, cisplatin related toxicity is a concern for many patients. In addition, not all patients with urothelial cancer are appropriate candidates for cisplatin therapy. (See",
"    <a class=\"local\" href=\"#H1495808759\">",
"     'Defining medical fitness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495809154\">",
"    <span class=\"h2\">",
"     Cisplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens used in the treatment of metastatic urothelial carcinoma include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       MVAC",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 15, 22),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 2, 15, 22),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      repeated every 28 days for six cycles (",
"      <a class=\"graphic graphic_table graphicRef64950 \" href=\"UTD.htm?28/7/28798\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       GC",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, 15) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 2), repeated every 28 days for a maximum of six cycles (",
"      <a class=\"graphic graphic_table graphicRef53016 \" href=\"UTD.htm?13/5/13406\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       PCG",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      before",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      on days 1 and 8), gemcitabine (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 8) and cisplatin (70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1), repeated every 21 days for a maximum of six cycles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data to support these recommendations are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495807279\">",
"    <span class=\"h3\">",
"     MVAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;MVAC is a standard first-line option based on the results of randomized clinical trials demonstrating improved survival outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. This was demonstrated in a multicenter trial of 269 patients with advanced urothelial carcinoma who were randomly assigned to treatment with either MVAC or single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/4\">",
"     4",
"    </a>",
"    ]. Compared to cisplatin, MVAC resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in the overall response rate (ORR, 39 versus 12 percent)",
"     </li>",
"     <li>",
"      A significant increase in median progression free survival (PFS, 10 versus 4 months)",
"     </li>",
"     <li>",
"      A significant improvement in median overall survival (OS, 13 versus 8 months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increasing the dose-intensity of MVAC by administering treatment every two weeks with G-CSF support has also been evaluated in an effort to improve long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, dose-intense treatment does not result in a clinically meaningful difference in overall survival. Given the toxicities of treatment, we do not administer dose-intense treatment in patients with advanced urothelial carcinoma.",
"   </p>",
"   <p>",
"    Toxicity is a major concern with MVAC therapy, particularly since many patients with bladder cancer are elderly or have multiple comorbidities. Myelosuppression, neutropenic fever, sepsis, mucositis, and nausea and vomiting are common. As an example, 54 percent of patients in one earlier series were hospitalized due to toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/27\">",
"     27",
"    </a>",
"    ]. Furthermore, toxicity-related deaths have been reported in most trials evaluating MVAC for advanced urothelial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. The use of hematopoietic growth factor support may ameliorate some of these toxicities, especially myelosuppression and mucositis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933456754\">",
"    <span class=\"h3\">",
"     GC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (GC) has similar efficacy and less toxicity compared with MVAC. This was demonstrated in a phase III trial, in which 405 patients were randomly assigned to either GC or MVAC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/1\">",
"     1",
"    </a>",
"    ]. Compared to MVAC, GC resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar overall response rate (ORR, 49 versus 36 percent).",
"     </li>",
"     <li>",
"      Similar time to progression (7 months in each arm).",
"     </li>",
"     <li>",
"      Similar overall survival (OS, 14 versus 15 months). At five years, there was also a similar five-year survival rate (13 and 15 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/2\">",
"       2",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Similar quality of life, though patients experienced less weight loss, a better performance status, and less fatigue.",
"     </li>",
"     <li>",
"      Less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity including neutropenia (71 versus 82 percent), neutropenic sepsis (2 versus 14 percent), and mucositis (1 versus 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This trial was designed to assess if GC is superior and was not powered to demonstrate equivalency between the two regimens, but given the similar efficacy and lesser toxicity, many consider GC rather than MVAC to be the standard first-line regimen for patients with advanced urothelial carcinoma of the bladder.",
"   </p>",
"   <p>",
"    Alternate dosing schedules with the GC regimen have used a three-week instead of four-week schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Although these different GC schedules have not been compared in randomized phase III trials, the results appear to be similar. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973607999\">",
"    <span class=\"h3\">",
"     PGC (paclitaxel plus GC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triplet combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (PGC) is another option for patients with metastatic urothelial carcinoma. This was demonstrated in European Organization for the Research and Treatment of Cancer Study 30987 (EORTC 30897), which enrolled 626 patients with advanced urothelial carcinoma (81 percent with primary bladder cancer) and randomly assigned them to treatment with GC or PGC for a maximum of six cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/34\">",
"     34",
"    </a>",
"    ]. Final results after a median follow-up of 4.6 years have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/35\">",
"     35",
"    </a>",
"    ]. Compared to GC, PGC resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in the ORR (56 versus 44 percent, p=.003).",
"     </li>",
"     <li>",
"      A trend towards an improvement in PFS (median, 8.3 versus 7.6 months, HR for progression 0.87, 95% CI 0.74-1.03).",
"     </li>",
"     <li>",
"      A trend towards longer OS (median, 16 versus 13 months, hazard ratio for death [HR] 0.85, 95% CI 0.72-1.02). When the analysis was restricted to patients who met all eligibility criteria (92 percent of the randomized population), PGC was associated with a significant increase in OS (median 16 versus 13 months, HR 0.82, 95% CI 0.68-0.98). In addition, PGC was associated with a significant improvement in OS among patients with primary bladder cancer compared to GC (median, 16 versus 12 months, HR 0.80, 95% CI 0.66-0.97).",
"     </li>",
"     <li>",
"      Increased incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity including neutropenia (65 versus 51 percent), fatigue (15 versus 11 percent), and infections (18 versus 14 percent), but a lower incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      thrombocytopenia (35 versus 52 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that PGC is a treatment option for patients with metastatic urothelial carcinoma and suggest it should be used for those with a bladder primary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495808204\">",
"    <span class=\"h2\">",
"     Carboplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are otherwise candidates for chemotherapy but are unable to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , we suggest the combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    . The benefit of carboplatin-based therapy was demonstrated in the European Organization for the Research and Treatment of Cancer (EORTC) trial 30986.",
"   </p>",
"   <p>",
"    In the EORTC 30986 study, 238 chemotherapy-na&iuml;ve patients with impaired renal function (glomerular filtration rate &lt;60 but &gt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a poor performance status (ECOG &ge;2) were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , carboplatin, plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (MCAVI) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/36\">",
"     36",
"    </a>",
"    ]. Compared to MCAVI, treatment with carboplatin plus gemcitabine resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher overall response rate (ORR, 41 versus 30 percent, respectively) that did not reach statistical significance.",
"     </li>",
"     <li>",
"      No difference in median overall survival (OS, 9 versus 8 months, hazard ratio [HR] for death, 0.94, 95% CI 0.72-1.22).",
"     </li>",
"     <li>",
"      No difference in median progression-free survival (PFS, 6 versus 4 months, HR for progression, 1.04, 95% CI 0.80-1.35).",
"     </li>",
"     <li>",
"      Less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity overall (9 versus 21 percent), including neutropenia (52 versus 63 percent) and febrile neutropenia (5 versus 15 percent). However, it was associated with a higher rate of serious thrombocytopenia (47 versus 18 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The final results of this trial suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is as effective as MCAVI with a better toxicity profile and support its use in patients with impaired renal function or a poor performance status (ECOG &ge;2) who are otherwise candidates for combination chemotherapy.",
"   </p>",
"   <p>",
"    Several other randomized trials have compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -based chemotherapy regimens with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. However, neither efficacy nor toxicity could be evaluated due to the small number of patients enrolled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495808211\">",
"    <span class=\"h2\">",
"     Nonplatinum regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens that combine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with a taxane (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ) rather than platinum have been evaluated with encouraging results. Paclitaxel plus gemcitabine appears to be more active than docetaxel plus gemcitabine in patients with advanced urothelial cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      results in objective response rates of 54 to 70 percent and median survival of 13 to 16 months [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/40-43\">",
"       40-43",
"      </a>",
"      ]. Toxicity with this combination is primarily hematologic, although severe pulmonary toxicity was reported in five patients in one series treated with paclitaxel on a weekly schedule [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two phase II trials reported the outcomes using the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with objective response rates of 33 and 52 percent and median overall survival of 13 and 15 months [",
"      <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495808218\">",
"    <span class=\"h2\">",
"     Single agent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of chemotherapy drugs have single agent activity in patients with metastatic urothelial carcinoma, either in the first-line setting or in previously treated patients. These include platinum compounds (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , vinca alkaloids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , vinflunine), anthracyclines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , taxanes (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/46-53\">",
"     46-53",
"    </a>",
"    ]. Responses to single agent chemotherapy are generally of short duration, and no consistent improvement in survival has been demonstrated. However, the activity with various single agents led to the development of combination regimens, most of which are cisplatin-based and discussed above. (See",
"    <a class=\"local\" href=\"#H1495808759\">",
"     'Defining medical fitness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495808759\">",
"    <span class=\"h1\">",
"     DEFINING MEDICAL FITNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who are candidates for chemotherapy should undergo evaluation of renal function. For patients with impaired renal function, reversible causes (ie, urinary tract obstruction secondary to a tumor mass) should be identified and treated prior to initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based therapy.",
"   </p>",
"   <p>",
"    An assessment that incorporates physiologic and biologic considerations can stratify patients into medically \"fit\" and \"frail\" populations, which is used to determine treatment options. The treatment options based on ability to tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    are discussed below.",
"   </p>",
"   <p>",
"    We agree with the use of criteria published by a consensus working group that defined medically frail patients in whom the decision to treat with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimen should be balanced with the consideration of the increased risks of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       WHO/ECOG",
"      </span>",
"      performance status 2 or greater (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 4",
"      </a>",
"      ) or a Karnofsky performance status of 60 to 70 percent or less (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Creatinine clearance less than 60",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      A hearing loss (measured at audiometry) of 25 dB at two contiguous frequencies",
"     </li>",
"     <li>",
"      Grade 2 or greater peripheral neuropathy (ie, sensory alteration or paresthesia, including tingling, but not interfering with activities of daily living)",
"     </li>",
"     <li>",
"      New York Heart Association class III or greater heart failure (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For medically fit patients (who do not have any of the criteria described above), we recommend initial treatment using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'First-line therapy'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    For patients who are unable to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    due to medical frailty or comorbidities, options include a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -based regimen (carboplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or carboplatin, gemcitabine, plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) or non-platinum based combination (eg, paclitaxel plus gemcitabine). A decision regarding treatment should take into account the patient&rsquo;s performance status and the clinician&rsquo;s medical judgment as to the patient&rsquo;s ability to tolerate chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good performance status (ie, ECOG performance status &lt;2) and are otherwise candidates for combination chemotherapy, we suggest a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -based regimen (ie, carboplatin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ). However, a non-platinum based combination would be a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H1495808204\">",
"       'Carboplatin-based regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1495808211\">",
"       'Nonplatinum regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a poor performance status who are not candidates for combination chemotherapy, treatment is based on patient and provider preference. Reasonable options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      or single agent chemotherapy. (See",
"      <a class=\"local\" href=\"#H1495808211\">",
"       'Nonplatinum regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1495808218\">",
"       'Single agent chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SECOND-LINE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a significant number of patients have an objective response to first-line therapy, most eventually progress and may be candidates for second-line chemotherapy.",
"   </p>",
"   <p>",
"    A number of contemporary chemotherapy agents have clinical activity after patients have progressed despite MVAC or GC. However, none of these agents have been approved for use in patients with metastatic urothelial carcinoma nor have their activity been validated in phase III clinical trials.",
"   </p>",
"   <p>",
"    These agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , vinflunine (not approved in the USA) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/55\">",
"     55",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/48,56\">",
"     48,56",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/51\">",
"     51",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/52\">",
"     52",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/47,57\">",
"     47,57",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/41\">",
"     41",
"    </a>",
"    ]. Reported response rates with single agents in the larger series have generally been 20 percent or less. Although these drugs have also been combined with either each other or with other agents, no one regimen is considered to be the standard second-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/58-63\">",
"     58-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with advanced bladder cancer who have failed an initial chemotherapy regimen should be encouraged to participate in clinical trials whenever possible.",
"   </p>",
"   <p>",
"    <strong>",
"     Vinflunine",
"    </strong>",
"    &mdash; Vinflunine is approved in Europe for second-line treatment of urothelial cancer based upon one trial that showed a benefit to treatment when compared to best supportive care. However, vinflunine is not approved in the United States.",
"   </p>",
"   <p>",
"    In the phase III trial, 370 previously treated patients were randomly assigned to either vinflunine or best supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/55\">",
"     55",
"    </a>",
"    ]. Compared to best supportive care, treatment with vinflunine resulted in a 9 percent objective response rate and an increase in survival (6.9 versus 4.6 months, hazard ratio 0.88, 95% CI 0.69-1.12). Imbalances in prognostic factors may have accounted for the lack of statistical significance in the primary analysis, with 10 percent more patients in the vinflunine arm than in the best supportive care arm having a better performance status.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    <strong>",
"     &mdash;",
"    </strong>",
"    Antifolates are known to be active in advanced bladder cancer, with a number of regimens incorporating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , including MVAC. Pemetrexed, a multitargeted antifolate, has shown activity in previously treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. As an example, in a Hoosier Oncology Group study, 47 previously treated patients received single agent pemetrexed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/65\">",
"     65",
"    </a>",
"    ]. The objective response rate (ORR) was 28 percent, including in three complete responses (6 percent). The median overall survival was 10 months.",
"   </p>",
"   <p>",
"    <strong>",
"     nAb-",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    <strong>",
"     &mdash;",
"    </strong>",
"    Nanoparticle, albumin-bound paclitaxel",
"    <strong>",
"    </strong>",
"    (nAb-paclitaxel), has demonstrated significant activity as second-line therapy in patients with metastatic urothelial cancer. As an example, the preliminary results of a phase II study of nAb-paclitaxel involving 36 patients were presented at the 2011 ASCO Genitourinary Oncology symposium. The overall response rate (ORR) was 33 percent and clinical benefit (ORR plus stable disease) was 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19897/abstract/66\">",
"     66",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing understanding of the tumor biology of urothelial cancers has highlighted the role of specific targets, particularly those in the vascular endothelial growth factor and epidermal growth factor pathways. Although agents that target these pathways are being actively evaluated in a number of studies, none has an established role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29431?source=see_link&amp;anchor=H5#H5\">",
"     \"Experimental systemic therapy of metastatic bladder cancer\", section on 'Angiogenesis inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NONUROTHELIAL BLADDER CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial carcinomas constitute the majority of bladder cancers in the United States, while squamous cell carcinomas and adenocarcinomas comprise a small fraction of bladder cancers. The management of nonurothelial bladder cancer, including chemotherapy for the treatment of advanced disease, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"     \"Nonurothelial bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advances in the management of advanced urothelial (transitional cell) carcinoma using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy have led to a substantial increase in survival. Despite this progress, metastatic disease is associated with a limited life expectancy and cures are infrequent.",
"     </li>",
"     <li>",
"      For patients with good performance status, adequate renal function and metastatic or inoperable, locally advanced urothelial cancer, we recommend initial treatment using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Reasonable options include MVAC (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and cisplatin),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus cisplatin (GC), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , gemcitabine, plus cisplatin (PGC). A choice between them is individualized based on patient and provider preferences. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'First-line therapy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For patients with impaired renal function, reversible causes (ie, urinary tract obstruction secondary to a tumor mass) should be identified and treated prior to initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based therapy. (See",
"      <a class=\"local\" href=\"#H1495808759\">",
"       'Defining medical fitness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced urothelial cancer who are not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      candidates, treatment should take into account the patient&rsquo;s performance status and ability to tolerate chemotherapy (see",
"      <a class=\"local\" href=\"#H1495808759\">",
"       'Defining medical fitness'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a good performance status",
"      <span class=\"nowrap\">",
"       (WHO/ECOG",
"      </span>",
"      performance status &lt;2) who are otherwise candidates for a combination regimen, options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -based regimens, a non-platinum based combination, and single agent chemotherapy. (See",
"      <a class=\"local\" href=\"#H1495808204\">",
"       'Carboplatin-based regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1495808211\">",
"       'Nonplatinum regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1495808218\">",
"       'Single agent chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other options including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      or single agent chemotherapy are reasonable alternatives. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who relapse following treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , multiple agents have modest activity including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , vinflunine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      . A decision regarding treatment should take into account the patient&rsquo;s performance status and the clinician&rsquo;s medical judgment as to the patient&rsquo;s ability to tolerate chemotherapy. &nbsp;(See",
"      <a class=\"local\" href=\"#H14\">",
"       'Second-line chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/1\">",
"      von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/2\">",
"      von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/3\">",
"      Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology 1980; 16:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/4\">",
"      Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/5\">",
"      Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/6\">",
"      Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/7\">",
"      Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/8\">",
"      Lin CC, Hsu CH, Huang CY, et al. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology 2007; 69:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/9\">",
"      Stadler WM, Hayden A, von der Maase H, et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002; 7:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/10\">",
"      Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/11\">",
"      Lorenzo-Romero JG, Salinas-S&aacute;nchez AS, Gim&eacute;nez-Bachs JM, et al. Prognostic implications of p53 gene mutations in bladder tumors. J Urol 2003; 169:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/12\">",
"      Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/13\">",
"      Edelman MJ, Meyers FJ, Miller TR, et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 2000; 55:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/14\">",
"      Koga F, Kitahara S, Arai K, et al. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 2000; 91:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/15\">",
"      Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/16\">",
"      Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature 1997; 385:123.",
"     </a>",
"    </li>",
"    <li>",
"     Stadler WM, Lerner SP, Groshen S, et al. Randomized trial of p53 targeted adjuvant therapy for patients with organ-confined node-negative urothelial bladder cancer (abstract #5017). J Clin Oncol 2009; 27:239s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/18\">",
"      Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/19\">",
"      Kim WJ, Kakehi Y, Yoshida O. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells. Int J Urol 1997; 4:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/20\">",
"      Kotoh S, Naito S, Yokomizo A, et al. Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 1997; 157:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/21\">",
"      Pendyala L, Velagapudi S, Toth K, et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 1997; 3:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/22\">",
"      Petrylak DP, Scher HI, Reuter V, et al. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 1994; 5:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/23\">",
"      Siegsmund MJ, Marx C, Seemann O, et al. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res 1999; 27:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/24\">",
"      Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/25\">",
"      Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/26\">",
"      Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/27\">",
"      Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989; 142:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/28\">",
"      Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002; 20:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/29\">",
"      Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/30\">",
"      Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993; 150:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/31\">",
"      Adamo V, Magno C, Spitaleri G, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology 2005; 69:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/32\">",
"      Soto Parra H, Cavina R, Latteri F, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002; 13:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/33\">",
"      Als AB, Sengelov L, Von Der Maase H. Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? Acta Oncol 2008; 47:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/34\">",
"      Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy (abstract #LBA 5030). J Clin Oncol 2007; 25:965s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/35\">",
"      Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/36\">",
"      De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/37\">",
"      Dogliotti L, Carten&igrave; G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007; 52:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/38\">",
"      Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/39\">",
"      Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/40\">",
"      Sternberg CN, Calabr&ograve; F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/41\">",
"      Meluch AA, Greco FA, Burris HA 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001; 19:3018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/42\">",
"      Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/43\">",
"      Calabr&ograve; F, Lorusso V, Rosati G, et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 2009; 115:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/44\">",
"      Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003; 98:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/45\">",
"      Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005; 92:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/46\">",
"      Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990; 322:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/47\">",
"      Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997; 15:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/48\">",
"      Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996; 156:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/49\">",
"      Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/50\">",
"      de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998; 78:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/51\">",
"      McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/52\">",
"      Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/53\">",
"      Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15:3441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/54\">",
"      Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/55\">",
"      Bellmunt J, Th&eacute;odore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/56\">",
"      Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/57\">",
"      Pronzato P, Vigani A, Pensa F, et al. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 1997; 20:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/58\">",
"      Bellmunt J, Cos J, Cl&egrave;ries R, et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 2002; 20:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/59\">",
"      Krege S, Rembrink V, B&ouml;rgermann C, et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 2001; 165:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/60\">",
"      Lin CC, Hsu CH, Huang CY, et al. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 2007; 18:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/61\">",
"      Soga N, Onishi T, Arima K, Sugimura Y. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int J Urol 2007; 14:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/62\">",
"      Suyama T, Ueda T, Fukasawa S, et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 2009; 39:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/63\">",
"      Albers P, Park SI, Niegisch G, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/64\">",
"      Galsky MD, Mironov S, Iasonos A, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19897/abstract/65\">",
"      Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24:3451.",
"     </a>",
"    </li>",
"    <li>",
"     Sridhar SS, Canil CM, Mukherjee SD, et al. Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma. J Clin Oncol 2011; suppl 7, abstract 241.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3000 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19897=[""].join("\n");
var outline_f19_27_19897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2740504\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1495807775\">",
"      Clinical factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1495807782\">",
"      Molecular factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FIRST-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1495809154\">",
"      Cisplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1495807279\">",
"      - MVAC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933456754\">",
"      - GC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H973607999\">",
"      - PGC (paclitaxel plus GC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1495808204\">",
"      Carboplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1495808211\">",
"      Nonplatinum regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1495808218\">",
"      Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1495808759\">",
"      DEFINING MEDICAL FITNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SECOND-LINE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NONUROTHELIAL BLADDER CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3000\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3000|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/7/28798\" title=\"table 2\">",
"      MVAC regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13406\" title=\"table 3\">",
"      Gemcitabine and cisplatin for metastatic urothelial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 4\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 5\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=related_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29431?source=related_link\">",
"      Experimental systemic therapy of metastatic bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=related_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=related_link\">",
"      Urethral cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=related_link\">",
"      Urethral cancer in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_27_19898="Management of problems related to intrauterine contraception";
var content_f19_27_19898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of problems related to intrauterine contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19898/contributors\">",
"     Gillian Dean, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19898/contributors\">",
"     Alisa B Goldberg, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19898/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/27/19898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/27/19898/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/27/19898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine contraception is generally well-tolerated, but side-effects and complications sometimes occur. This topic will review management of the most common problems related to intrauterine contraception with the copper T380A and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing intrauterine devices (IUDs) (TCu380A, ParaGard&reg; and LNg IUD, Mirena&reg;). General issues related to intrauterine contraception and insertion and removal of IUDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=see_link\">",
"     \"Insertion and removal of an intrauterine contraceptive device\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several terms are used to describe intrauterine contraception, including intrauterine device (IUD) and intrauterine contraceptive (IUC); the progestin-containing device is also referred to as an intrauterine system (IUS). In this topic, we use the term IUD for all types of intrauterine contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPULSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first year of use, expulsion occurs in 3 to 10 percent of women with the TCu380A and 6 percent of women with the LNg IUD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Risk factors for expulsion include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nulliparity",
"     </li>",
"     <li>",
"      Menorrhagia",
"     </li>",
"     <li>",
"      Severe dysmenorrhea",
"     </li>",
"     <li>",
"      Prior expulsion",
"     </li>",
"     <li>",
"      Age less than 20 years",
"     </li>",
"     <li>",
"      Insertion immediately after a second trimester abortion or postpartum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms suggesting partial or complete expulsion include cramping, vaginal discharge, intermenstrual or postcoital bleeding or spotting, male or female dyspareunia, or lengthened or absent strings. The woman may palpate all or part of the IUD in the vagina. However, some IUD expulsions are asymptomatic. Because women who experience asymptomatic IUD expulsion may not present for evaluation, it is important to teach all IUD users to check their IUD strings periodically. If complete expulsion occurs and the woman does not become pregnant, she may notice that her periods are changing back to their pre-IUD insertion pattern.",
"   </p>",
"   <p>",
"    Any woman with symptoms suggestive of expulsion should be evaluated promptly. If the IUD is visible in the endocervical canal or vagina, it should be removed and should not be re-used or re-inserted.",
"   </p>",
"   <p>",
"    If the IUD or its strings are not visible, complete expulsion may have occurred. The diagnosis of complete expulsion requires ultrasound confirmation that the IUD is not in the uterus, followed by x-ray documentation that the IUD is not in the abdomen or pelvis (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Strings not visible'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A new IUD can be inserted after expulsion if desired; standard criteria for insertion of an IUD should be met (eg, pregnancy excluded, no active infection). It is unknown whether changing the IUD type (copper or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    ) at reinsertion will reduce the risk of recurrent expulsion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=see_link\">",
"     \"Insertion and removal of an intrauterine contraceptive device\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11444509\">",
"    <span class=\"h2\">",
"     Recurrent expulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of re-expulsion appears to be higher than the risk of expulsion after initial insertion, but minimal data are available. In one study, 124 women had a TCu-200B intrauterine device inserted following an expulsion: the cumulative re-expulsion rates after 6 and 12 months were 21.7 and 31.4 per 100 women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on risk factors for repeat expulsion are sparse. Recurrent expulsion may be due to faulty technique or uterine factors (eg, severe flexion, abnormally shaped uterine cavity, patulous internal cervical os) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When replacing an IUD after an expulsion, assuming the initial placement was not immediately postabortion or postdelivery, we recommend performing the placement under sonographic guidance to ensure that the IUD is placed at the uterine fundus. If a second expulsion occurs and the woman wishes to try a third IUD insertion, we recommend sonographic or hysteroscopic evaluation of the endometrial cavity to exclude anomalies or pathology that may be responsible for the expulsions (eg, adhesions, obstructing fibroids).&nbsp;If the cavity is abnormal, we recommend not attempting a third insertion. If the cavity is normal, a third IUD insertion can be attempted after",
"    <strong>",
"    </strong>",
"    counseling the women that she is at high risk for repeat expulsion. Furthermore, we counsel these patients that women with a history of past expulsions may be at increased risk of subsequent IUD failure even when the replaced IUD remains in situ [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2938880\">",
"    <span class=\"h1\">",
"     MALPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proper placement of an IUD is in the fundal portion of the uterine cavity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57867 \" href=\"UTD.htm?24/5/24664\">",
"     image 1",
"    </a>",
"    ). An IUD is malpositioned if any part of it extends into the myometrium or endocervical canal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57867 \" href=\"UTD.htm?24/5/24664\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50768 \" href=\"UTD.htm?10/13/10450\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62490 \" href=\"UTD.htm?6/2/6177\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76355 \" href=\"UTD.htm?18/29/18903\">",
"     image 4",
"    </a>",
"    ), if it is rotated, or if it is located distant from the fundus and within the lower uterine segment. Approximately 10 percent of IUDs are malpositioned [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/10\">",
"     10",
"    </a>",
"    ], but not all malpositioned IUDs require removal (as discussed below).",
"   </p>",
"   <p>",
"    A copper IUD is relatively easy to detect with ultrasound, as it gives a strong echo. The LNg IUD is more difficult to identify because only the proximal and distal ends of the vertical arms produce a detectable echo; this may or may not be enough to confirm the location of the device in the uterus. The LNg IUD produces a dark sonographic shadow, particularly on transvaginal ultrasound, that can also aid in its localization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If ultrasound performed for any reason reveals that the IUD is malpositioned, the patient should be asked whether she is experiencing any symptoms of a displaced IUD, such as new or especially bothersome cramping, heavy menstrual bleeding, or intermenstrual bleeding or spotting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. If the woman is symptomatic, the IUD should be removed and, ideally, a new IUD is placed at the same visit to avoid a gap in contraception. We often perform replacements under ultrasound guidance to be sure of proper fundal positioning.",
"   </p>",
"   <p>",
"    There are limited data to guide the management of an incidental finding of a displaced IUD in a woman who is asymptomatic. Theoretically, a small change in position should not affect the contraceptive effects of the progestin or copper that is released. Data from a randomized trial of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD support this hypothesis, showing no difference in pregnancy rates between intracervically and fundally placed devices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/13\">",
"     13",
"    </a>",
"    ]. There are no similar studies of copper IUDs. Pregnancy appears to be more common in women with malpositioned copper IUDs than correctly positioned copper IUDs, but it is unknown whether the malpositioned IUD is the cause or the result of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The extent of malposition (eg, low intrauterine displacement versus arms embedded in myometrium) is also a probable factor affecting the risk of contraceptive failure. In a series of 28 women with malpositioned IUDs left in situ and followed for two years, there were no unintended pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, women who had malpositioned devices removed or expelled often did not initiate another highly effective method of contraception and became pregnant.",
"   </p>",
"   <p>",
"    As a general rule, if a LNG or Copper T380 IUD is located in the lower uterine segment or near (but not at) the fundus, we tend to leave it in place as most of these IUDs will not be expelled, and some migrate to a more fundal position [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. If an IUD is below the internal cervical os, we recommend removal because expulsion may follow, and may not be detected. Ideally, a new IUD will be placed or another highly effective contraceptive method (eg, implant) will be initiated at the same visit in order to avoid an interruption in contraception.",
"   </p>",
"   <p>",
"    In a case series of 18 women in whom a LNg-releasing IUD was displaced towards the cervical canal on sonographic examination, the IUD was easily repositioned toward the fundus using an alligator forceps in 17 patients; however, in 3 of these patients, it became malpositioned again within two months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/19\">",
"     19",
"    </a>",
"    ]. At present, we do not attempt to reposition malpositioned IUDs; instead, we follow the management plans described above. However, if the success of repositioning IUDs is confirmed in other studies, it may prove to be an effective method of managing a symptomatic malpositioned IUD.",
"   </p>",
"   <p>",
"    Malposition may be more likely when placement is difficult, such as in women with a distorted uterine cavity, adenomyosis or obesity. In these cases, placement by an experienced clinician and use of ultrasound guidance may reduce the risk of malposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STRINGS NOT VISIBLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the IUD strings are not visible on speculum examination, possible explanations from most to least common are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The IUD is in situ, but the strings are curled and retracted into the endocervical canal or uterine cavity, or they are broken. Uterine enlargement secondary to fibroids or pregnancy, or rotation of the IUD can also cause retraction of strings;",
"     </li>",
"     <li>",
"      The IUD has been expelled;",
"     </li>",
"     <li>",
"      The IUD has perforated the uterus and is in the myometrium or abdomen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first step is to exclude pregnancy. If the woman is pregnant, an ultrasound should be performed to determine the location of the IUD and the pregnancy. Management depends upon the location of the IUD, the trimester of pregnancy, and the patient's desire to continue or terminate the pregnancy (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If the woman is not pregnant, we twist a cytobrush in the endocervical canal to try to draw the string out of the canal. If the string becomes visible with this maneuver, no additional action is required.",
"   </p>",
"   <p>",
"    If this maneuver is unsuccessful, we examine the endocervical canal with a uterine sound or an endocervical speculum to determine if the IUD is in the process of being expelled. Usually the strings become more visible in this situation, but they can also become twisted and remain hidden from view. If the IUD is in the cervix, we remove it using a grasping forceps (eg, Bozeman uterine packing forceps or alligator forceps), IUD hook, IUD thread retriever, or Kelly clamp, and, if the woman desires, we replace it with a new IUD. Prophylactic antibiotics are unnecessary when removing the IUD from the uterus or cervix.",
"   </p>",
"   <p>",
"    If these maneuvers do not locate the strings, we obtain an ultrasound examination to localize the IUD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/20\">",
"     20",
"    </a>",
"    ]. Interim contraception should be provided if ultrasonography is scheduled for a later date. If ultrasound examination shows that the IUD is in the proper position within the uterine cavity, the woman may continue to use it for contraception (despite the strings not being accessible). We suggest performing an ultrasound annually for the first several years to ensure that the IUD has remained in place [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/21\">",
"     21",
"    </a>",
"    ]. After several years, the risk of expulsion is so low that the use of confirmatory ultrasound may be discontinued; the patient should be instructed to return if she develops symptoms suggestive of IUD expulsion or displacement.",
"   </p>",
"   <p>",
"    If she wishes to discontinue the IUD, an alligator forceps, Bozeman uterine packing forceps, or an IUD hook can be used to grasp and remove it. Ultrasound guidance can be helpful if blind attempts to grasp the IUD are unsuccessful. Analgesia, if needed, can be provided by infusing a local anesthetic (eg, 5 mL of 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) into the uterine cavity with an angiocatheter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/22\">",
"     22",
"    </a>",
"    ] or by paracervical block, either alone or in combination with conscious sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/23\">",
"     23",
"    </a>",
"    ]. The cervix can be softened, if needed, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    in order to facilitate the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/23\">",
"     23",
"    </a>",
"    ]. The IUD can also be removed using suction: attach a small cannula to a manual uterine aspirator (eg, IPAS syringe) or an electric vacuum aspirator. Hysteroscopic removal is rarely necessary, but is the next step if other methods have been unsuccessful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If ultrasound examination does not locate the IUD, we obtain anteroposterior and lateral upright plain radiographs of the entire abdomen and pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/20\">",
"     20",
"    </a>",
"    ]. Both the TCu380A and the LNg IUD are radiopaque; therefore, if the IUD is not visualized on x-ray examination, expulsion has occurred. Expulsion cannot be diagnosed without x-ray documentation unless the expulsion was noted by the user. It is usually impossible to detect an IUD that is located outside the uterus with ultrasound. A new IUD can be inserted, if desired.",
"   </p>",
"   <p>",
"    If x-ray shows that the IUD is located outside the uterine cavity, a perforation has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PERFORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation occurs during IUD insertion and complicates about 1 in 1000 insertion procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/4\">",
"     4",
"    </a>",
"    ]. Risk factors include clinician inexperience in IUD placement, an immobile uterus, a retroverted uterus, and the presence of a myometrial defect (pre-existing or created during the procedure by the uterine sound or the IUD inserter). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=see_link\">",
"     \"Insertion and removal of an intrauterine contraceptive device\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since perforation may not be recognized immediately, many clinicians re-examine the patient six weeks after IUD insertion to look for signs and symptoms of perforation, such as shortening of string length. Perforations diagnosed after the insertion procedure have been attributed to spontaneous IUD migration; although difficult to disprove, we think this explanation is implausible.",
"   </p>",
"   <p>",
"    Ultrasound is used to determine the location of a perforated IUD (x-ray can be used if ultrasound is not available). As discussed above, if ultrasound examination does not reveal the location of the IUD, the IUD may have been expelled. An x-ray of the pelvis and abdomen should be obtained since expulsion cannot be diagnosed reliably without x-ray documentation.",
"   </p>",
"   <p>",
"    Once perforation has been identified, experts recommend treating the woman with antibiotics as for pelvic inflammatory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .) Although serious complications following perforation are uncommon, most experts, but not all, recommend that any perforated IUD be removed unless the surgical risk is excessive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The major concerns of nonintervention are adhesion formation and their sequelae, and perforation into bowel, bladder, or blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the IUD is in the abdomen or perforating through the myometrium, operative laparoscopy is the preferred method of removal and can be performed electively in asymptomatic patients, and is usually successful [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/30\">",
"     30",
"    </a>",
"    ]. If laparoscopy is unsuccessful due to extensive adhesions, the procedure should be converted to a laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the IUD is embedded in the myometrium, operative hysteroscopy may be required for removal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/33\">",
"     33",
"    </a>",
"    ]. An IUD that has migrated completely through the myometrium may be anywhere in the pelvis. Most frequently, it is found encased in adhesions, adherent to the sigmoid colon or omentum, or freely floating in the posterior cul de sac (pouch of Douglas) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/28,32,34-38\">",
"     28,32,34-38",
"    </a>",
"    ]. There are case reports of IUD perforation into the bladder; intravesical location of an IUD may cause urinary tract symptoms. Perforation into the rectum has also been reported, but modern IUDs, including the LNg IUD and various forms of the TCu380A, have not been associated with intestinal injury. IUDs embedded in the omentum can be hard to find because radiographically they appear to be located in the pelvis, but when the patient is placed into Trendelenburg position for laparoscopy, the omentum and IUD can shift into the upper abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/39\">",
"     39",
"    </a>",
"    ]. An intraoperative x-ray can help localize the IUD.",
"   </p>",
"   <p>",
"    Patients whose IUDs have perforated and been recovered may be offered another IUD, but we recommend placing future IUDs in such patients under ultrasound guidance.",
"   </p>",
"   <p>",
"    IUD perforation is not a contraindication to future labor and vaginal delivery, as the uterine defect is small. A literature review did not identify any case reports of rupture of a pregnant uterus associated with prior IUD perforation.",
"   </p>",
"   <p>",
"    Uterine perforation during insertion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PARTNER FEELS STRINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IUD strings should be trimmed to approximately 3 to 4 cm from the external os. If the strings are cut too short, the partner may experience irritation during intercourse. If this occurs, we suggest trimming the strings flush with the cervix, or replacing the IUD and leaving longer strings. Some women do not want their partners to know that they are using contraception for fear of violence or birth control sabotage. The IUD may be used in these patients by trimming the string flush with the cervix so that it cannot be detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a woman with a longstanding IUD develops new severe cramping or abdominal tenderness, she should be evaluated for pelvic inflammatory disease, ectopic pregnancy, threatened or incomplete miscarriage, and IUD expulsion or perforation.",
"   </p>",
"   <p>",
"    Dysmenorrhea is often worse in the first few cycles after insertion of a copper IUD, and along with unscheduled bleeding, is one of the primary reasons for copper IUD discontinuation. However, discontinuation rates for pain are low (0.1 to 2.4 percent) in both copper and LNg IUD users [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/1,40-44\">",
"     1,40-44",
"    </a>",
"    ]. Mild to moderate dysmenorrhea can be treated with nonsteroidal antiinflammatory drugs (NSAIDs) begun at the onset of menses and maintained for the first three days of each menstrual cycle (",
"    <a class=\"graphic graphic_table graphicRef71912 \" href=\"UTD.htm?28/52/29516\">",
"     table 1",
"    </a>",
"    ). Women with severe dysmenorrhea and a copper IUD should consider the LNg IUD or choose another method of contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ABNORMAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCu380A and the LNg IUD are associated with changes in uterine bleeding patterns, which may include intermenstrual bleeding (both IUDs), increased volume of menstrual bleeding (primarily TCu380A), prolonged menstrual bleeding (primarily LNg IUD), or amenorrhea (primarily LNg IUD). Counseling women about the expected changes in bleeding patterns prior to insertion may enhance adherence to the method. Unexpected changes in bleeding patterns or changes that are not tolerable to the patient should be evaluated.",
"   </p>",
"   <p>",
"    Possible causes of new onset abnormal bleeding after prolonged use of IUDs include displacement of the device, pregnancy (intrauterine or ectopic), and infection, as well as gynecologic disorders of the cervix or uterus (eg, leiomyomas, polyps, endometrial cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/24,45\">",
"     24,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of unscheduled bleeding in women using contraception\", section on 'Intrauterine contraception (IUD)'",
"    </a>",
"    .) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women over age 40 or with risk factors for endometrial cancer who develop new abnormal bleeding should undergo evaluation of the endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/24,47\">",
"     24,47",
"    </a>",
"    ]. It is important to first exclude IUD displacement, infection, and pregnancy as possible causes of the abnormal bleeding. Although some clinicians remove the IUD before sampling the uterus, an endometrial biopsy using a Pipelle can be performed with the IUD in place. If an adequate tissue sample cannot be obtained, the IUD should be removed before resampling. We do not send the IUD for culture since colonization without infection is common [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic endometritis is a common finding in endometrial biopsies of women who have used an IUD for more than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/47\">",
"     47",
"    </a>",
"    ]. We do not treat this histological diagnosis unless the patient also has pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=see_link&amp;anchor=H20#H20\">",
"     \"Endometritis unrelated to pregnancy\", section on 'Intrauterine foreign objects, intrauterine growths, and radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645067949\">",
"    <span class=\"h2\">",
"     TCu380a IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The copper IUD is associated with increased menstrual flow both in length of menses and in amount of blood loss. A prospective study of over 1900 Copper T380A users found that many side effects related to bleeding and pain decreased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/40\">",
"     40",
"    </a>",
"    ]. However, most of the improvement was in symptoms occurring during menses, whereas most intermenstrual complaints (such as unscheduled bleeding) did not decrease with time. NSAIDs appear to decrease menstrual blood loss and bleeding duration, particularly in women with heavy or prolonged bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of unscheduled bleeding in women using contraception\", section on 'Intrauterine contraception (IUD)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    <br/>",
"    We remove the IUD if the woman complains of menorrhagia and experiences a clinically significant fall in hemoglobin. These patients may consider another method of contraception or insertion of a LNg IUD since the mean per cycle blood loss for the LNg IUD is 5 mL versus 55 mL for the copper IUD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/4,49\">",
"     4,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645067956\">",
"    <span class=\"h2\">",
"     LNg IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LNg IUD is associated with a reduction in menstrual blood loss; LNg IUD users report fewer bleeding or spotting days per month compared with noncontraceptors and users of copper IUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41\">",
"     41",
"    </a>",
"    ]. However, many LNg IUD users experience episodes of unscheduled bleeding, which may be limited to spotting. The incidence of unpredictable bleeding is greatest in the initial six months of use, although episodes may occur throughout usage.",
"   </p>",
"   <p>",
"    The proportion of users with amenorrhea increases with duration of use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/50\">",
"     50",
"    </a>",
"    ]. At six months of use, 44 percent of users have amenorrhea, 25 percent experience oligomenorrhea, and 25 percent experience unscheduled spotting; the remainder have either normal or heavy bleeding. At 24 months of use, 50 percent have amenorrhea, 25 percent have oligomenorrhea, and 11 percent have spotting; again the remainder report either normal or heavy bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/51\">",
"     51",
"    </a>",
"    ]. Amenorrhea in LNg IUD users is due to endometrial decidualization and atrophy; at one year, the majority of women have ovulatory cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41,50,52\">",
"     41,50,52",
"    </a>",
"    ]. The decrease in uterine bleeding that occurs in most LNg IUD users is associated with a corresponding increase in hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/3,41\">",
"     3,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in bleeding patterns, primarily unscheduled spotting and bleeding and prolonged bleeding episodes, are the main reasons for premature LNg IUD removal. Some early studies reported amenorrhea was the principal cause for removal, but subsequent studies found that amenorrhea was associated with continuation; this change may reflect improved counseling about expected changes in bleeding patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41,53,54\">",
"     41,53,54",
"    </a>",
"    ]. Complaints of menstrual problems, including amenorrhea and spotting, decline with use beyond one year and with patient age greater than 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41,54\">",
"     41,54",
"    </a>",
"    ]. Options for treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of unscheduled bleeding in women using contraception\", section on 'Intrauterine contraception (IUD)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any LNg IUD user presenting with new onset of amenorrhea should have a pregnancy test; once pregnancy is excluded, further pregnancy tests are not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169361467\">",
"    <span class=\"h1\">",
"     VAGINAL DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women report increased vaginal discharge with the IUD; this is usually normal leukorrhea and not a sign of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic inflammatory disease (PID) is most strongly associated with the insertion process and with the user's risk of acquiring a sexually transmitted disease (STD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The risk of infection is greatest in the first 20 days after insertion (range 1 to 10 per 1000 women undergoing insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/55,57\">",
"     55,57",
"    </a>",
"    ]) and is rare thereafter (1.4 per 1000 women undergoing insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/55\">",
"     55",
"    </a>",
"    ]), and does not increase with prolonged IUD use. PID following insertion is due to a polymicrobial infection, usually involving anaerobic bacteria from the cervix and vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/33\">",
"     33",
"    </a>",
"    ]. Risk factors include bacterial vaginosis, cervicitis, and contamination of the endometrial cavity at insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/24,33\">",
"     24,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infections more than one month after insertion are generally due to a newly acquired STD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/33,58\">",
"     33,58",
"    </a>",
"    ]. The LNg IUD is probably protective against PID from newly acquired STDs because progestin thickens cervical mucus, making it less permeable to sperm and bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/59\">",
"     59",
"    </a>",
"    ]. Although the copper IUD does not offer this same protection, it does not appear to increase the risk of PID or of serious infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a woman has clinical signs and symptoms of PID, standard antibiotic treatment should be initiated. The World Health Organization (WHO) has stated that the IUD does not have to be removed if the provider feels the advantages of continuing the method outweigh the risks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, this recommendation was based upon data from three retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. The only randomized trial (published after the WHO statement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/61\">",
"     61",
"    </a>",
"    ]) showed that removing the IUD before initiating medical therapy increased the rate of clinical improvement of mild to moderate PID compared with patients in whom the IUD was left in situ during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/66\">",
"     66",
"    </a>",
"    ]. Therefore, in settings where a replacement IUD is readily available, we recommend administering appropriate antibiotics followed immediately by removal of the IUD, as well as use of an alternative method of contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Antibiotics should be administered before IUD removal because bacteremia may occur with removal of an IUD in the setting of PID [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/67\">",
"     67",
"    </a>",
"    ]. We send the IUD for culture, as microbiology results can be helpful if the patient does not respond to empiric therapy.",
"   </p>",
"   <p>",
"    If the woman wants the IUD replaced, a new IUD may be inserted three months after the infection has resolved if she is no longer at elevated risk of PID. Because infection is associated with insertion, clinicians should avoid premature replacement of IUDs unless replacement is clinically indicated and a good alternative is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In resource poor settings where a replacement IUD is not available, it may be preferable to treat mild to moderate PID without removal of the IUD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic women who have laboratory evidence of gonorrhea or chlamydia should receive standard treatment. Although IUD removal is not necessary, the patient's appropriateness for continued use of an IUD should be reassessed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vaginitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with bacterial vaginosis, trichomonas vaginalis, or candidiasis should receive standard treatment without IUD removal. Whether women with IUDs are at higher risk of developing bacterial vaginosis is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=see_link\">",
"     \"Bacterial vaginosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link\">",
"     \"Trichomonas vaginalis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link\">",
"     \"Candida vulvovaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Actinomyces on cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinomyces, a Gram positive anaerobic bacillus, is part of the normal flora of the gastrointestinal tract and is commonly present in normal vaginal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/70\">",
"     70",
"    </a>",
"    ]. Although there are several case reports of endometritis, pelvic inflammatory disease, pelvic abscess, and retroperitoneal fibrosis associated with actinomyces in IUD users [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/71,72\">",
"     71,72",
"    </a>",
"    ], the identification of actinomyces in the vagina or cervix by any laboratory technique is not diagnostic of disease and is not predictive of development of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 7 percent of women using an IUD have actinomyces-like organisms on a Papanicolaou (Pap) test [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/74\">",
"     74",
"    </a>",
"    ]; only about half of these women will have positive actinomyces cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. If the cervical cytology report indicates actinomyces-like organisms, then we suggest that the woman be notified of the finding and examined. If she is asymptomatic, the cytology finding probably represents colonization. There is no evidence to support antibiotic treatment or IUD removal in asymptomatic women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/33,74\">",
"     33,74",
"    </a>",
"    ]. The woman should be informed that she should contact her health care provider if she develops signs of pelvic inflammatory disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, if the woman shows signs or symptoms of pelvic infection (pelvic mass or pain, uterine tenderness), antibiotics should be administered followed by removal of the IUD, which is sent for anaerobic culture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/24\">",
"     24",
"    </a>",
"    ]. Removal of the IUD is important because actinomyces preferentially grow on foreign bodies. The diagnosis can be difficult to make and therapy is individualized, depending on the initial burden of disease and the clinical and radiological responses to antibiotics. Actinomyces is sensitive to penicillin; tetracyclines are used for penicillin allergic patients. Although some experts advocate oral therapy for very early pelvic actinomyces [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/75\">",
"     75",
"    </a>",
"    ], accurate diagnosis of early stages of infection is difficult given the nonspecific clinical features of even advanced disease. Therefore, actinomyces infection is generally treated with intravenous antibiotics. Prolonged intravenous therapy (weeks to months) is indicated for confirmed actinomyces-related tuboovarian abscess or disseminated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/76\">",
"     76",
"    </a>",
"    ]; surgery may also be necessary. Infectious disease consultation is important for these cases. We counsel women with a history of actinomyces abscesses against future IUD use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38452?source=see_link&amp;anchor=H4#H4\">",
"     \"Abdominal actinomycosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38452?source=see_link&amp;anchor=H8#H8\">",
"     \"Abdominal actinomycosis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, in one review, only 50 percent of women with pelvic actinomyces abscesses had actinomyces organisms identified on a prior Papanicolaou smear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LNg IUD seems to have a lower incidence of actinomyces-like organisms noted on Pap smear than copper IUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Toxic shock syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of staphylococcal and streptococcal toxic shock syndrome attributed to IUD use have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link\">",
"     \"Staphylococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=see_link\">",
"     \"Treatment of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1334751797\">",
"    <span class=\"h1\">",
"     EXPIRED AND DIFFICULT TO REMOVE IUDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women sometimes present with an IUD that has been retained beyond its &lsquo;expiration&rsquo; date. If the string is visible, the IUD should be removed.",
"   </p>",
"   <p>",
"    If the string is not visible, the location should be determined by ultrasound. If the IUD is confirmed to be intrauterine, we suggest removal in the office or an appropriately equipped ambulatory procedure room using an alligator forceps, Bozeman uterine packing forceps, or IUD hook. Difficult removals should be performed under ultrasound guidance or using a hysteroscope with a grasper [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/81\">",
"     81",
"    </a>",
"    ]. Sometimes conscious sedation is required.",
"   </p>",
"   <p>",
"    If removal is unsuccessful and the woman is asymptomatic, premenopausal, and does not currently require contraception, one option is to leave the IUD in place, but there are no data about the safety of this approach. If she develops symptoms (pain, abnormal bleeding), the IUD should be removed, which may require anesthesia and operative hysteroscopy, particularly if the IUD is embedded in the myometrium. The risks and benefits of anesthesia and an operative procedure need to be weighed against those of leaving the IUD in place indefinitely (eg, rare case reports of pelvic actinomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]). These decisions are patient-specific and need to be made on a case by case basis.",
"   </p>",
"   <p>",
"    If the woman requires contraception, removal and replacement depend on the type of IUD. Studies of long-term use of the copper T380A IUD show high contraceptive efficacy and safety for up to 20 years of use, although data for use beyond 15 years are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/84\">",
"     84",
"    </a>",
"    ]. For the LNg IUD (Mirena&reg;), efficacy may decrease after five years and is only proven through seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41\">",
"     41",
"    </a>",
"    ]. Older inert IUDs can be left in place indefinitely, but generally are removed and replaced with newer medicated IUDs due to the lower efficacy of the inert devices. In general, we would remove any IUD when the woman reaches menopause (ie, amenorrhea for one year). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of intrauterine contraception\", section on 'Menopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of pregnancy is highest in the first year after IUD insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/2\">",
"     2",
"    </a>",
"    ]. Malposition of the IUD is a risk factor (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76355 \" href=\"UTD.htm?18/29/18903\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who conceive with an IUD in place have a greater risk of adverse pregnancy outcomes compared with the general obstetrical population. Risks include miscarriage, preterm delivery, chorioamnionitis and septic abortion. Among women who conceive with an IUD in situ, the miscarriage rate is 40 to 50 percent, a rate more than two-fold higher than that of women who become pregnant without an IUD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of adverse events is highest when the IUD is left in place, although women who have the IUD removed still have an increased risk of adverse events throughout pregnancy, including preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/87\">",
"     87",
"    </a>",
"    ]. There does not appear to be an increased risk of birth defects in pregnancies conceived and carried with an IUD in situ, although there are insufficient data to draw definitive conclusions about the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    exposure on the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a woman becomes pregnant with an IUD in place, we first determine whether the pregnancy is intrauterine or extrauterine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .) We suggest the following steps in the evaluation and management of intrauterine pregnancy in a patient with an IUD in situ:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11445031\">",
"    <span class=\"h2\">",
"     First trimester intrauterine pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the IUD strings are visible on speculum examination, remove the IUD to decrease the risk of subsequent miscarriage and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/4\">",
"     4",
"    </a>",
"    ]. Antibiotics are unnecessary.",
"   </p>",
"   <p>",
"    If the strings are not visible and the patient wishes to continue the pregnancy, we suggest removing the IUD under ultrasound guidance using an alligator forceps or a Bozeman uterine packing forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Removal can also be attempted by hysteroscopy. Data on hysteroscopic removal of IUDs in early pregnancy are limited; therefore, it is not clear whether this technique poses greater or lesser risk of pregnancy loss than instrument removal under ultrasound guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. We recommend antibiotic prophylaxis when instrument removals are performed during pregnancy, including when IUD removal is to be followed by pregnancy termination (see below). If the IUD cannot be removed by pulling the strings or removed easily using either instruments under sonographic guidance or hysteroscopy, the IUD may be left in situ. The risks of pregnancy loss with aggressive attempts at IUD removal must be weighed against the risks of adverse maternal and fetal outcomes later in pregnancy, including infection and preterm delivery, if the IUD is left in place.",
"   </p>",
"   <p>",
"    If the woman desires pregnancy termination, IUD removal can be performed at the time of the termination. Manual or electric vacuum aspiration or an instrument such as an IUD hook, Bozeman uterine packing forceps, alligator forceps, ring forceps, or ovum forceps can be used to remove the IUD. However, if strings are visible upon initial diagnosis and there may be a significant delay until pregnancy termination can be performed, we recommend pulling the strings to remove the IUD as soon as possible, since the strings may no longer be visible as the uterus grows and removal may be more difficult later in gestation.",
"   </p>",
"   <p>",
"    In the setting of miscarriage with IUD in place, we suggest removing the IUD and prescribing antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg twice a day or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    500 mg four times a day for seven days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11445039\">",
"    <span class=\"h2\">",
"     Second trimester pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We counsel these women that if the IUD remains in situ, there is an increased risk of preterm labor and delivery (fourfold increase), second trimester fetal loss, and infection, but no proven increase in risk of birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/4,33,45,93\">",
"     4,33,45,93",
"    </a>",
"    ]. In addition, in a LNg IUD user, there are theoretical fetal risks associated with intrauterine hormone exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/88\">",
"     88",
"    </a>",
"    ]. Removal of the IUD may cause rupture of membranes, bleeding, pregnancy loss, or fetal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/94\">",
"     94",
"    </a>",
"    ]; however, if the IUD is removed or expelled without complications, there is no increased risk of miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/4,33,95\">",
"     4,33,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given this information, for pregnancies after 12 weeks, we suggest removing the IUD by pulling on the strings if the strings are visible and removal is unlikely to disrupt the placenta or membranes (based upon ultrasound localization of the IUD and placenta) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/45,90,95-97\">",
"     45,90,95-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the strings are not visible in the early second trimester, the IUD may be removed under ultrasound guidance if removal appears feasible, the IUD is not located behind the placenta, and it does not appear to be incorporated into the gestational sac. In particular, we recommend ultrasound guided removal in these cases if the IUD is in the lower uterine segment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/95\">",
"     95",
"    </a>",
"    ]. If the IUD appears embedded in the placenta, located behind the placenta, or protrudes into the gestational sac, we suggest leaving the IUD in situ.",
"   </p>",
"   <p>",
"    In the late second trimester, if the strings are not visible, the IUD should be left in place. The patient should be counseled that her risks of miscarriage and premature delivery are increased relative to women whose IUDs may be easily removed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HORMONAL SIDE EFFECTS OF LNg-IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal side effects (including hirsutism, acne, weight change, nausea, headache, mood changes, and breast tenderness) are the most common reasons for elective LNg IUD removal in the first 36 months of use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/59\">",
"     59",
"    </a>",
"    ]. LNg IUD users also have more discontinuations because of hair and skin changes and headache than users of copper IUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41,59,98\">",
"     41,59,98",
"    </a>",
"    ]. These complaints may be due to the systemic effects of levonorgestrel, even though plasma levonorgestrel levels are low [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/59\">",
"     59",
"    </a>",
"    ]. In the first five years of use, approximately 12 percent of women prematurely discontinue the LNg IUD because of hormone-attributable complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41,54,99\">",
"     41,54,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ABNORMAL CERVICAL CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with IUDs are not at increased risk of cervical intraepithelial neoplasia (CIN); they should undergo routine assessment in accordance with American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines on cervical cancer screening. Benign cervical changes, such as cervical inflammation and metaplasia, are more common in IUD users than non-users [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/41,100-102\">",
"     41,100-102",
"    </a>",
"    ], but cervical cancer is less common in IUD users. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of intrauterine contraception\", section on 'Cancer risk reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If an ablative or excisional procedure is required for management of CIN, it may be performed with the IUD in situ. For loop electrosurgical excision procedures (LEEP), some clinicians perform the LEEP in two segments, holding the strings anteriorly while removing the posterior segment of the biopsy and then holding the strings posteriorly for removal of the anterior segment. This approach requires more skill than the usual LEEP and increases the chance that a suboptimal specimen will be obtained. Another cumbersome technique involves tying a suture to the strings and bringing the lengthened strings through a hollow plastic tube, which is placed in the endocervical canal to protect the enclosed strings during the LEEP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/27/19898/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend the following approach for LEEP or ablative procedures with an IUD in situ: push the strings into the cervical canal using a cytobrush and then perform the procedure in the usual fashion. After completing the procedure, tease the strings back out using a cytobrush. If the strings become damaged during the procedure, the IUD may be managed as in a patient with retracted strings (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Strings not visible'",
"    </a>",
"    above). However, some providers find this approach more difficult than the two segment approach.",
"   </p>",
"   <p>",
"    We do not recommend prophylactic antibiotics for these procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"       \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the intrauterine device (IUD) strings are not visible on speculum examination, possible explanations are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The IUD is in situ, but the strings are retracted into the endocervical canal or uterine cavity. The strings may be teased into the correct position. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Strings not visible'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The IUD has been expelled. This requires supportive ultrasound and x-ray documentation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Expulsion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The IUD has perforated the uterus and is in the myometrium or abdomen. We suggest surgical removal rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient is pregnant. The IUD may be in situ, but the pregnant uterus has drawn the strings up into the uterine cavity so they are no longer visible. Alternatively, the device may have been expelled or perforated, and thus not protected the women against pregnancy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malpositioned (greater than 20 mm from the fundus in a normal uterus) IUDs in symptomatic women should be removed. In asymptomatic women who wish to continue IUD use, the IUD may be left in place if it is located above the internal os and if the woman would not replace it or choose another highly effective method of contraception. We suggest removal of malpositioned IUDs located below the level of the internal os. (See",
"      <a class=\"local\" href=\"#H2938880\">",
"       'Malposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with a history of expulsion, perforation, or malposition of a past IUD, the next IUD should be placed under sonographic guidance. (See",
"      <a class=\"local\" href=\"#H11444509\">",
"       'Recurrent expulsion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a woman with a longstanding IUD develops new severe cramping or abdominal tenderness, she should be evaluated for pelvic inflammatory disease, ectopic pregnancy, miscarriage, and IUD expulsion or perforation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild and moderate dysmenorrhea can often be controlled with nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Possible causes of new onset abnormal bleeding in women after prolonged use of IUDs include displacement of the device, pregnancy (intrauterine or ectopic), infection, as well as gynecologic disorders of the cervix or uterus (eg, leiomyomas, polyps, endometrial cancer). In women over age 40 or with risk factors for endometrial cancer who develop abnormal bleeding, the endometrium should be evaluated. Any LNg IUD user presenting with new onset of amenorrhea should have a pregnancy test. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Abnormal bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who develop symptomatic pelvic inflammatory disease, we suggest administration of appropriate antibiotics followed by removal of the IUD rather than treatment with the IUD in situ (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An alternative method of contraception should be prescribed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pelvic inflammatory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard antibiotic treatment without IUD removal may be offered to asymptomatic women with laboratory evidence of gonorrhea or chlamydia. The patient should be assessed for appropriateness for continued IUD use. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The identification of actinomyces in the vagina or cervix by any laboratory technique is not diagnostic of disease and is not predictive of development of disease. We suggest avoiding treatment of actinomyces in asymptomatic women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Actinomyces on cervical cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among women who conceive with an IUD that remains in situ, the risk of miscarriage is 40 to 50 percent, a rate twice as high as that of the general obstetric population. Whenever possible, we suggest removing the IUD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If loop electrosurgical excision procedure (LEEP) or an ablative procedure is to be performed with IUD in situ, we suggest leaving the IUD in situ and either pushing the strings into the cervical canal to get them out of the way or performing a LEEP in two segments. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Abnormal cervical cytology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/1\">",
"      Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception 1999; 60:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/2\">",
"      Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/3\">",
"      Sivin I, Schmidt F. Effectiveness of IUDs: a review. Contraception 1987; 36:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/4\">",
"      Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1987; 753:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/5\">",
"      Zhang J, Feldblum PJ, Chi IC, Farr MG. Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception 1992; 46:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/6\">",
"      Bahamondes L, D&iacute;az J, Marchi NM, et al. Performance of copper intrauterine devices when inserted after an expulsion. Hum Reprod 1995; 10:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/7\">",
"      el-Zeneiny AH, Ammar AR, Badawi SZ. Expulsion of the intrauterine devices Lippes loop size 30 mm. J Egypt Med Assoc 1969; 52:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/8\">",
"      Tepper NK, Zapata LB, Jamieson DJ, Curtis KM. Use of intrauterine devices in women with uterine anatomic abnormalities. Int J Gynaecol Obstet 2010; 109:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/9\">",
"      Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006; 21:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/10\">",
"      Braaten KP, Benson CB, Maurer R, Goldberg AB. Malpositioned intrauterine contraceptive devices: risk factors, outcomes, and future pregnancies. Obstet Gynecol 2011; 118:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/11\">",
"      Palo P. Transabdominal and transvaginal ultrasound detection of levonorgestrel IUD in the uterus. Acta Obstet Gynecol Scand 1997; 76:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/12\">",
"      Benacerraf BR, Shipp TD, Bromley B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are a source of pelvic pain and abnormal bleeding. Ultrasound Obstet Gynecol 2009; 34:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/13\">",
"      Pakarinen P, Luukkainen T. Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception 2005; 72:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/14\">",
"      Inal MM, Ertop&ccedil;u K, Ozelmas I. The evaluation of 318 intrauterine pregnancy cases with an intrauterine device. Eur J Contracept Reprod Health Care 2005; 10:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/15\">",
"      Anteby E, Revel A, Ben-Chetrit A, et al. Intrauterine device failure: relation to its location within the uterine cavity. Obstet Gynecol 1993; 81:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/16\">",
"      Petta CA, Fa&uacute;ndes D, Pimentel E, et al. The use of vaginal ultrasound to identify copper T IUDs at high risk of expulsion. Contraception 1996; 54:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/17\">",
"      Morales-Rosello J. Spontaneous upward movement of lowly placed T-shaped IUDs. Contraception 2005; 72:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/18\">",
"      Faundes D, Perdigao A, Faundes A, et al. T-shaped IUDs accomodate to their position during the first three months after insertion. Contraception 2000; 62:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/19\">",
"      Ber A, Seidman DS. Management of the malpositioned levonorgestrel-releasing intrauterine system. Contraception 2012; 85:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/20\">",
"      Peri N, Graham D, Levine D. Imaging of intrauterine contraceptive devices. J Ultrasound Med 2007; 26:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/21\">",
"      Marchi NM, Castro S, Hidalgo MM, et al. Management of missing strings in users of intrauterine contraceptives. Contraception 2012; 86:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/22\">",
"      G&uuml;ney M, Oral B, Mungan T. Efficacy of intrauterine lidocaine for removal of a \"lost\" intrauterine device: a randomized, controlled trial. Obstet Gynecol 2006; 108:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/23\">",
"      Prabhakaran S, Chuang A. In-office retrieval of intrauterine contraceptive devices with missing strings. Contraception 2011; 83:102.",
"     </a>",
"    </li>",
"    <li>",
"     Hatcher, RA, Trussell, J, Stewart, F, et al. Contraceptive Technology, 19th ed, Ardent Media, Inc., New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/25\">",
"      Chen CP, Hsu TC, Wang W. Ileal penetration by a Multiload-Cu 375 intrauterine contraceptive device. A case report with review of the literature. Contraception 1998; 58:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/26\">",
"      Adoni A, Ben Chetrit A. The management of intrauterine devices following uterine perforation. Contraception 1991; 43:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/27\">",
"      Zakin D, Stern WZ, Rosenblatt R. Complete and partial uterine perforation and embedding following insertion of intrauterine devices. II. Diagnostic methods, prevention, and management. Obstet Gynecol Surv 1981; 36:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/28\">",
"      Markovitch O, Klein Z, Gidoni Y, et al. Extrauterine mislocated IUD: is surgical removal mandatory? Contraception 2002; 66:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/29\">",
"      Vasquez P, Schreiber CA. The missing IUD. Contraception 2010; 82:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/30\">",
"      Gill RS, Mok D, Hudson M, et al. Laparoscopic removal of an intra-abdominal intrauterine device: case and systematic review. Contraception 2012; 85:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/31\">",
"      Andersson K, Ryde-Blomqvist E, Lindell K, et al. Perforations with intrauterine devices. Report from a Swedish survey. Contraception 1998; 57:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/32\">",
"      Ozgun MT, Batukan C, Serin IS, et al. Surgical management of intra-abdominal mislocated intrauterine devices. Contraception 2007; 75:96.",
"     </a>",
"    </li>",
"    <li>",
"     Speroff, L, Darney, P. A Clinical Guide for Contraception, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/34\">",
"      Dietrick DD, Issa MM, Kabalin JN, Bassett JB. Intravesical migration of intrauterine device. J Urol 1992; 147:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/35\">",
"      El-Hefnawy AS, El-Nahas AR, Osman Y, Bazeed MA. Urinary complications of migrated intrauterine contraceptive device. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/36\">",
"      Singh I. Intravesical Cu-T emigration: an atypical and infrequent cause of vesical calculus. Int Urol Nephrol 2007; 39:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/37\">",
"      Khan ZA, Khan SA, Williams A, Mobb GE. Intravesical migration of levonorgestrel-releasing intrauterine system (LNG-IUS) with calculus formation. Eur J Contracept Reprod Health Care 2006; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/38\">",
"      Heinberg EM, McCoy TW, Pasic R. The perforated intrauterine device: endoscopic retrieval. JSLS 2008; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/39\">",
"      Nitke S, Rabinerson D, Dekel A, et al. Lost levonorgestrel IUD: diagnosis and therapy. Contraception 2004; 69:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/40\">",
"      Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception 2009; 79:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/41\">",
"      Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/42\">",
"      Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception 1989; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/43\">",
"      Meirik O, Rowe PJ, Peregoudov A, et al. The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception 2009; 80:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/44\">",
"      Jensen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 2008; 77:22.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson, AL, Hatcher, RA, Zieman, M, et al. Managing Contraception. Tiger, Georgia: Bridging the Gap Foundation, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/46\">",
"      R&ouml;nnerdag M, Odlind V. Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity. Contraception 2007; 75:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/47\">",
"      Ozalp S, Kabukcuoglu S, Tanir HM. Should endometrial hyperplasia be regarded as a reason for abnormal uterine bleeding in users of the intrauterine contraceptive device? Eur J Contracept Reprod Health Care 2003; 8:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/48\">",
"      Tsanadis G, Kalantaridou SN, Kaponis A, et al. Bacteriological cultures of removed intrauterine devices and pelvic inflammatory disease. Contraception 2002; 65:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/49\">",
"      Milsom I, Andersson K, Jonasson K, et al. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception 1995; 52:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/50\">",
"      R&ouml;nnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999; 78:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/51\">",
"      Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/52\">",
"      Nilsson CG, L&auml;hteenm&auml;ki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984; 41:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/53\">",
"      Fa&uacute;ndes A, Alvarez F, D&iacute;az J. A Latin American experience with levonorgestrel IUD. Ann Med 1993; 25:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/54\">",
"      Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000; 107:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/55\">",
"      Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/56\">",
"      Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. Obstet Gynecol 1988; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/57\">",
"      Walsh T, Grimes D, Frezieres R, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 1998; 351:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/58\">",
"      Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/59\">",
"      Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991; 77:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/60\">",
"      Feldblum PJ, Caraway J, Bahamondes L, et al. Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment. Contraception 2005; 72:187.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Improving access to quality care in family planning. In: Medical Eligibility criteria for contraceptive use. 3rd ed, Geneva, Switzerland, 2003.",
"    </li>",
"    <li>",
"     Rinehart, W. WHO updates medical eligibility criteria for contraceptices. Info Reports. Johns Hopkins University population information program. Baltimore, MD. April 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/63\">",
"      Larsson B, Wennergren M. Investigation of a copper-intrauterine device (Cu-IUD) for possible effect on frequency and healing of pelvic inflammatory disease. Contraception 1977; 15:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/64\">",
"      S&ouml;derberg G, Lindgren S. Influence of an intrauterine device on the course of an acute salpingitis. Contraception 1981; 24:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/65\">",
"      Teisala K. Removal of an intrauterine device and the treatment of acute pelvic inflammatory disease. Ann Med 1989; 21:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/66\">",
"      Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003; 107:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/67\">",
"      Murray S, Hickey JB, Houang E. Significant bacteremia associated with replacement of intrauterine contraceptive device. Am J Obstet Gynecol 1987; 156:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/68\">",
"      Shoubnikova M, Hellberg D, Nilsson S, M&aring;rdh PA. Contraceptive use in women with bacterial vaginosis. Contraception 1997; 55:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/69\">",
"      Hodoglugil NN, Aslan D, Bertan M. Intrauterine device use and some issues related to sexually transmitted disease screening and occurrence. Contraception 2000; 61:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/70\">",
"      Persson E, Holmberg K, Dahlgren S, Nilsson L. Actinomyces israelii in the genital tract of women with and without intra-uterine contraceptive devices. Acta Obstet Gynecol Scand 1983; 62:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/71\">",
"      Fiorino AS. Intrauterine contraceptive device-associated actinomycotic abscess and Actinomyces detection on cervical smear. Obstet Gynecol 1996; 87:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/72\">",
"      Keebler C, Chatwani A, Schwartz R. Actinomycosis infection associated with intrauterine contraceptive devices. Am J Obstet Gynecol 1983; 145:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/73\">",
"      Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 1999; 180:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/74\">",
"      Westhoff C. IUDs and colonization or infection with Actinomyces. Contraception 2007; 75:S48.",
"     </a>",
"    </li>",
"    <li>",
"     Mandell, GL, Bennett, JE, Dolin, R. Principles and Practice of Infectious Diseases, 6th ed, Elsevier, Ch 253 Agents of Actinomycosis, 2005. p.2929.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/76\">",
"      Sudhakar SS, Ross JJ. Short-term treatment of actinomycosis: two cases and a review. Clin Infect Dis 2004; 38:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/77\">",
"      Merki-Feld GS, Lebeda E, Hogg B, Keller PJ. The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper- and levonorgestrel-releasing intrauterine devices. Contraception 2000; 61:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/78\">",
"      Klug CD, Keay CR, Ginde AA. Fatal toxic shock syndrome from an intrauterine device. Ann Emerg Med 2009; 54:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/79\">",
"      Venkataramanasetty R, Aburawi A, Phillip H. Streptococcal toxic shock syndrome following insertion of an intrauterine device--a case report. Eur J Contracept Reprod Health Care 2009; 14:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/80\">",
"      Gisser JM, Fields MC, Pick N, et al. Invasive group a streptococcus associated with an intrauterine device and oral sex. Sex Transm Dis 2002; 29:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/81\">",
"      Turok DK, Gurtcheff SE, Gibson K, et al. Operative management of intrauterine device complications: a case series report. Contraception 2010; 82:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/82\">",
"      Yeg&uuml;ez JF, Martinez SA, Sands LR, Hellinger MD. Pelvic actinomycosis presenting as malignant large bowel obstruction: a case report and a review of the literature. Am Surg 2000; 66:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/83\">",
"      Nugteren SK, Ouwendijk RJ, Jonkman JG, et al. Colitis and lower abdominal mass by Actinomyces israelii in a patient with an IUD. Neth J Med 1996; 49:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/84\">",
"      Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007; 75:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/85\">",
"      Moschos E, Twickler DM. Intrauterine devices in early pregnancy: findings on ultrasound and clinical outcomes. Am J Obstet Gynecol 2011; 204:427.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/86\">",
"      Ganer H, Levy A, Ohel I, Sheiner E. Pregnancy outcome in women with an intrauterine contraceptive device. Am J Obstet Gynecol 2009; 201:381.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/87\">",
"      Brahmi D, Steenland MW, Renner RM, et al. Pregnancy outcomes with an IUD in situ: a systematic review. Contraception 2012; 85:131.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Selected practice recommendations for contraceptive use. file://www.who.int/reproductivehealth/publications/family_planning/9241562846index/en/index.html (Accessed on January 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/89\">",
"      Sachs BP, Gregory K, McArdle C, Pinshaw A. Removal of retained intrauterine contraceptive devices in pregnancy. Am J Perinatol 1992; 9:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/90\">",
"      Sviggum O, Skjeldestad FE, Tuveng JM. Ultrasonically guided retrieval of occult IUD in early pregnancy. Acta Obstet Gynecol Scand 1991; 70:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/91\">",
"      Assaf A, Gohar M, Saad S, et al. Removal of intrauterine devices with missing tails during early pregnancy. Contraception 1992; 45:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/92\">",
"      Lin JC, Chen YO, Lin BL, Valle RF. Outcome of removal of intrauterine devices with flexible hysteroscopy in early pregnancy. J Gynecol Surg 1993; 9:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/93\">",
"      Hopkins MR, Agudelo-Suarez P, El-Nashar SA, et al. Term pregnancy with intraperitoneal levonorgestrel intrauterine system: a case report and review of the literature. Contraception 2009; 79:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/94\">",
"      Weissmann-Brenner A, Lerner A, Peleg D. Transverse limb reduction and intrauterine device: case report and review of the literature. Eur J Contracept Reprod Health Care 2007; 12:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/95\">",
"      Schiesser M, Lapaire O, Tercanli S, Holzgreve W. Lost intrauterine devices during pregnancy: maternal and fetal outcome after ultrasound-guided extraction. An analysis of 82 cases. Ultrasound Obstet Gynecol 2004; 23:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/96\">",
"      Stubblefield PG, Fuller AF Jr, Foster SC. Ultrasound-guided intrauterine removal of intrauterine contraceptive devices in pregnancy. Obstet Gynecol 1988; 72:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/97\">",
"      Koetsawang S, Rachawat D, Piya-Anant M. Outcome of pregnancy in the presence of intrauterine device. Acta Obstet Gynecol Scand 1977; 56:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/98\">",
"      Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception 1991; 44:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/99\">",
"      Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/100\">",
"      Fahmy K, Ismail H, Sammour M, et al. Cervical pathology with intrauterine contraceptive devices--a cyto-colpo-pathological study. Contraception 1990; 41:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/101\">",
"      Misra JS, Engineer AD, Tandon P. Cervical cytology associated with levonorgestrel contraception. Acta Cytol 1995; 39:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/102\">",
"      Kaplan B, Orvieto R, Hirsch M, et al. The impact of intrauterine contraceptive devices on cytological findings from routine Pap smear testing. Eur J Contracept Reprod Health Care 1998; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/27/19898/abstract/103\">",
"      Bailey AP, Darracott MM. Loop electrosurgical excision procedure with an intrauterine device in place. Am J Obstet Gynecol 2010; 203:291.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5422 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19898=[""].join("\n");
var outline_f19_27_19898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPULSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11444509\">",
"      Recurrent expulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2938880\">",
"      MALPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STRINGS NOT VISIBLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PERFORATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PARTNER FEELS STRINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ABNORMAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H645067949\">",
"      TCu380a IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H645067956\">",
"      LNg IUD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169361467\">",
"      VAGINAL DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Actinomyces on cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1334751797\">",
"      EXPIRED AND DIFFICULT TO REMOVE IUDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11445031\">",
"      First trimester intrauterine pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11445039\">",
"      Second trimester pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HORMONAL SIDE EFFECTS OF LNg-IUD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ABNORMAL CERVICAL CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5422\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5422|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/5/24664\" title=\"diagnostic image 1\">",
"      Ultrasound images of in situ intrauterine device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/13/10450\" title=\"diagnostic image 2\">",
"      Ultrasound of embedded IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/2/6177\" title=\"diagnostic image 3\">",
"      3D ultrasound of displaced IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/29/18903\" title=\"diagnostic image 4\">",
"      Pregnancy with IUD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5422|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/52/29516\" title=\"table 1\">",
"      NSAID dose for medical therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38452?source=related_link\">",
"      Abdominal actinomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=related_link\">",
"      Endometritis unrelated to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=related_link\">",
"      Insertion and removal of an intrauterine contraceptive device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=related_link\">",
"      Management of unscheduled bleeding in women using contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8519?source=related_link\">",
"      Treatment of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_27_19899="Eur study preg result asthma";
var content_f19_27_19899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Odds ratios (95 percent CI) for outcomes of pregnancy in asthmatic vs control women in a large population based study",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        All subjects, n = 36,985",
"       </td>",
"       <td class=\"subtitle1\">",
"        Asthma most severe, n = 1,396",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal mortality",
"       </td>",
"       <td>",
"        1.21 (1.08-1.35)",
"       </td>",
"       <td>",
"        1.28 (0.76-2.17)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia",
"       </td>",
"       <td>",
"        1.15 (1.08-1.23)",
"       </td>",
"       <td>",
"        1.42 (1.09-1.86)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preterm birth (&lt;37 weeks)",
"       </td>",
"       <td>",
"        1.15 (1.09-1.21)",
"       </td>",
"       <td>",
"        1.56 (1.27-1.90)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low birth weight (&lt;2500 gm)",
"       </td>",
"       <td>",
"        1.21 (1.14-1.29)",
"       </td>",
"       <td>",
"        1.98 (1.52-2.59)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital malformations",
"       </td>",
"       <td>",
"        1.05 (0.99-1.10)",
"       </td>",
"       <td>",
"        1.08 (0.83-1.40)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Kallen, B, Rydhstroem, H, Aberg, A. Asthma during pregnancy - a population based study. Eur J Epidem 2000; 16:167.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19899=[""].join("\n");
var outline_f19_27_19899=null;
var title_f19_27_19900="Features of idiopathic interstitial pneumonias";
var content_f19_27_19900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinguishing features of the idiopathic interstitial pneumonias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        AIP",
"       </td>",
"       <td class=\"subtitle1\">",
"        DIP",
"       </td>",
"       <td class=\"subtitle1\">",
"        UIP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prodrome",
"       </td>",
"       <td>",
"        Abrupt (1 to 2 weeks)",
"       </td>",
"       <td>",
"        Subacute (weeks to months)",
"       </td>",
"       <td>",
"        Chronic (&gt;12 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiography",
"       </td>",
"       <td>",
"        Diffuse, bilateral air-space opacification",
"       </td>",
"       <td>",
"        Ground-glass opacity in lower lung zones",
"       </td>",
"       <td>",
"        <p>",
"         Bilateral reticular opacities",
"        </p>",
"        <p>",
"         Honeycombing",
"        </p>",
"        <p>",
"         Lower zone predominance",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HRCT features",
"       </td>",
"       <td>",
"        <p>",
"         Bilateral, symmetric areas of ground-glass opacity",
"        </p>",
"        <p>",
"         Bilateral air space consolidation",
"        </p>",
"       </td>",
"       <td>",
"        Diffuse ground-glass opacity in middle and lower lungzones",
"       </td>",
"       <td>",
"        <p>",
"         Intralobular interstitial opacities",
"        </p>",
"        <p>",
"         Irregular interlobular septal thickening",
"        </p>",
"        <p>",
"         Traction bronchiectasis and honeycombing",
"        </p>",
"        <p>",
"         Lower zone predominance",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histopathologic features",
"       </td>",
"       <td>",
"        Diffuse, uniform organizing diffuse alveolar damage (hyaline membranes)",
"       </td>",
"       <td>",
"        Diffuse, uniform intraalveolar macrophage accumulation",
"       </td>",
"       <td>",
"        Variegated, patchy, subpleural interstitial fibrosisand honeycombing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment",
"       </td>",
"       <td>",
"        <p>",
"         Mechanical ventilation",
"        </p>",
"        <p>",
"         Glucocorticoid responsiveness unknown",
"        </p>",
"       </td>",
"       <td>",
"        Glucocorticoid responsive",
"       </td>",
"       <td>",
"        Poor response to glucocorticoids or cytotoxic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prognosis",
"       </td>",
"       <td>",
"        60 percent mortality in &lt;6 months",
"       </td>",
"       <td>",
"        5 percent mortality in 5 years",
"       </td>",
"       <td>",
"        50 to 70 percent mortality in 5 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AIP: acute interstitial pneumonia; UIP: usualinterstitial pneumonia; DIP: desquamative interstitial pneumonia; HRCT: high resolution CT scan.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19900=[""].join("\n");
var outline_f19_27_19900=null;
var title_f19_27_19901="Platelet count and bleeding in ITP";
var content_f19_27_19901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship between platelet count and bleeding in immune thrombocytopenia (ITP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This scattergraph shows the correlation between bleeding manifestations and the platelet count in patients with immune thrombocytopenia (ITP). Bleeding manifestations were defined as: 0: no bleeding; 1: minimal bleeding after trauma; 2: spontaneous but self-limited bleeding; 3: spontaneous bleeding requiring special attention, such as nasal packs for epistaxis; and 4: severe, life-threatening bleeding. Spontaneous bleeding begins at platelet counts below 40,000/microL, while severe (grades 3 and 4) spontaneous bleeding was primarily seen at platelet counts below 10,000/microL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lacy JV, Penner JA. Semin Thromb Haemost 1977; 3:160.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19901=[""].join("\n");
var outline_f19_27_19901=null;
var title_f19_27_19902="Effect precondition time I";
var content_f19_27_19902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Effect of ischemic preconditioning decreases over time",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of ischemic preconditioning on an ischemic response during balloon angioplasty in patients with coronary heart disease. The percent of patients who do not have an ischemic response during the first balloon inflation decreased as the duration of time since the last spontaneous episode of angina increased. An ischemic episode was least likely in those who had had a spontaneous episode of angina within the previous six hours (first column).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lim, R Lasky, WK, J Am Coll Cardiol 1997; 30:1461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19902=[""].join("\n");
var outline_f19_27_19902=null;
var title_f19_27_19903="Retinal vascularization";
var content_f19_27_19903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal vascularization - left eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vascularization of the retina begins at approximately 16 weeks' gestation at the optic nerve and proceeds peripherally. Retinal vessels reach the ora serrata (the periphery of the eye) on the nasal side at 32 weeks' gestation and on the temporal side at 36 to 40 weeks' gestation. The numbers in the figure are weeks of gestation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_27_19903=[""].join("\n");
var outline_f19_27_19903=null;
